Biomaterials 76 (2016) 321e343
Contents lists available at ScienceDirect
Biomaterials
journal homepage: www.elsevier.com/locate/biomaterials
Review
Current advances and future perspectives in extrusion-based
bioprinting
Ibrahim T. Ozbolat a, b, *, Monika Hospodiuk a, b
a
b
Engineering Science and Mechanics Department, The Pennsylvania State University, University Park, PA, 16802, USA
The Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, 16802, USA
a r t i c l e i n f o
a b s t r a c t
Article history:
Received 14 June 2015
Received in revised form
23 October 2015
Accepted 29 October 2015
Available online 31 October 2015
Extrusion-based bioprinting (EBB) is a rapidly growing technology that has made substantial progress
during the last decade. It has great versatility in printing various biologics, including cells, tissues, tissue
constructs, organ modules and microfluidic devices, in applications from basic research and pharmaceutics to clinics. Despite the great benefits and flexibility in printing a wide range of bioinks, including
tissue spheroids, tissue strands, cell pellets, decellularized matrix components, micro-carriers and cellladen hydrogels, the technology currently faces several limitations and challenges. These include impediments to organ fabrication, the limited resolution of printed features, the need for advanced bioprinting solutions to transition the technology bench to bedside, the necessity of new bioink
development for rapid, safe and sustainable delivery of cells in a biomimetically organized microenvironment, and regulatory concerns to transform the technology into a product. This paper, presenting a
first-time comprehensive review of EBB, discusses the current advancements in EBB technology and
highlights future directions to transform the technology to generate viable end products for tissue engineering and regenerative medicine.
© 2015 Elsevier Ltd. All rights reserved.
Keywords:
Extrusion-based bioprinting
Biofabrication
Tissue and organ printing
Bioink
1. Introduction
The pressure or extrusion-based method has been used for quite
a long time for various processes such as shape forming of metals
and plastics [1]. In the late 1990s, with the emergence of fuseddeposition modeling (FDM), the extrusion-based solid-freeform
fabrication approach demonstrated three-dimensional (3D) printing of intricate geometries with controlled porous architecture [2].
This innovative approach was later introduced into tissue engineering via 3D printing of porous scaffolds [3], which act as temporary housing for cells to support their attachment, growth and
proliferation. In this regard, several pioneering works have been
demonstrated in the literature, including the development of
printable biomaterials and 3D printing approaches for scaffold
fabrication by Hutmatcher's group [4e6] and efforts in investigating modeling and design aspects for solid-freeform fabrication
of tissue scaffolds by Hollister's group [7e9]. With the advent of
printing living cells, the emergence of the first bioprinting
technologies via other means such as laser-based bioprinting [10]
and inkjet-based bioprinting [11], the investigation of extrusionbased bioprinting (EBB) [12] has begun. While there is a misconception about the term “bioprinting” as it has been interchangeably
used with 3D printing of inert materials applied to tissue engineering, the authors consider providing a definition of bioprinting
to the reader. Bioprinting can be defined as the spatial patterning of
living cells and other biologics by stacking and assembling them
using a computer-aided layer-by-layer deposition approach for
fabrication of living tissue and organ analogs for tissue engineering,
regenerative medicine, pharmacokinetic, and other biological
studies [13], and shall not be used interchangeably with 3D printing
of inert materials.
The first investigation in the context of EBB was the printing of
living cells using the bioplotting approach, in which hydrogel bioink was extruded and bioplotted into a liquid medium, resulting in
high flexural and mechanical strength and cell proliferation rate
[14]. The fledgling technology later received enormous attention
* Corresponding author. Engineering Science and Mechanics Department, The Pennsylvania State University, University Park, PA, 16802, USA.
E-mail address: ito1@psu.edu (I.T. Ozbolat).
http://dx.doi.org/10.1016/j.biomaterials.2015.10.076
0142-9612/© 2015 Elsevier Ltd. All rights reserved.
322
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
and advanced rapidly. Although several groups, including Sun and
his coworkers [15,16], investigated the technology by encapsulating
cells in hydrogel solutions, the versatility of the technology allowed
other researchers to adopt novel bioink materials into the EBB
technology. In 2004, Mironov and Forgacs introduced the concept
of printing scaffold-free cell aggregates for bioprinting living tissues and organs [17e19]. They considered printing cells in clusters
in a spheroid shape on a hydrogel glue called “biopaper” [20] and
investigated bioprinting vascular constructs in 3D. After some
initial attempts at bioprinting spheroids and assembling them
vertically, the technology rapidly evolved into generating feasible
outcomes and resulted in the fabrication of blood vessels [21].
Further modifications have been applied to the technology, and it
currently enables printing tissue constructs that do not require
significant vascularization such as thin or hollow (i.e., skin, nerve
and vasculature) and avascular (i.e., cartilage) tissues [22].
Due its versatility, affordability and ability to print porous constructs, EBB is now utilized by numerous researchers worldwide,
and the technology has already paved the way to bioprint cells
[23e25], tissues [26], tissue constructs [27], organ modules [28]
and tissue/organ-on-a-chip devices [27], with long-term expectations of printing functional scale-up organs [29]. A wide variety of
tissue constructs have been successfully engineered by means of
EBB, including but not limited to cartilage [30], vasculature [21],
bone [31], skin [32], liver [25,33] and cardiac [34] tissue constructs.
Currently, EBB technology has been commercialized by several
companies, and a number of bioprinters are widely available for
new bioprinting researchers entering the field or researchers using
bioprinting as an application in fields such as biology, pharmacy
and medicine [35]. The technology has been adopted into various
fields and includes basic research in areas such as cancer research
[36], tissue engineering [37,38], pharmaceutics for drug testing [39]
and tissue printing for transplantation and clinics [40].
Although several reviews have been published in the area of
bioprinting of tissues and organs [22,41,42], no study has investigated EBB solely and thoroughly. This article presents a comprehensive review of EBB for the first time covering its working
principles, applicable bioink materials, process configurations and
bioprinter technologies and providing the reader with current advances and future perspectives and directions. Transformative approaches should also be discussed, including transitional
approaches to get the technology from bench to bedside, advancements in the area of bioink processing for EBB, bioprintingmediated genes for advanced gene therapy applications, bioprinting of new types of organs and other novel concepts that have
the potential to make a breakthrough in EBB science and
technology.
2. Background
2.1. Working principles
The EBB technique is a combination of a fluid-dispensing system
and an automated robotic system for extrusion and bioprinting,
respectively [12]. During bioprinting, bioink is dispensed by a
deposition system, under the control of a computer, resulting in the
precise deposition of cells encapsulated in cylindrical filaments of
desired 3D custom-shaped structures. This rapid fabrication technique provides better structural integrity due to the continuous
deposition of filaments. Moreover, this method easily can incorporate computer software such as computer-aided design (CAD)
software, which enables users to load a CAD file to automatically
print the structure [43]. The CAD file can be obtained from medical
images such as MRI and CT scans or a free-form design per demand
[44].
The fluid-dispensing system can be driven by a pneumatic-,
mechanical- (piston or screw-driven) or solenoid-based system, as
shown in Fig. 1A pneumatic-based system utilizes pressurized air
using a valve-free (Fig. 1A1) or a valve-based (Fig. 1A2) configuration. Although the valve-free configuration has been widely used
due to its simplicity, the valve-based configuration can be preferable because of its controlled pressure and pulse frequency for
high-precision applications [16]. Mechanical micro-extrusion systems utilize piston- (Fig. 1B1) or screw-driven (Fig. 1B2) configurations. The piston-driven configuration generally provides more
direct control over the flow of bioink through the nozzle [45], while
the screw-driven configuration may give more spatial control and is
beneficial for dispensing bioinks with higher viscosities [46].
However, the screw-driven configuration can generate larger
pressure drops along the nozzle, which can potentially harm the
loaded cells. Thus, the rotating screw gear needs to be carefully
designed in order to use it in EBB. Both types of mechanical microextrusion can work synergistically, i.e., the screw-driven configuration melts polycaprolactone (PCL) before deposition while the
piston-driven syringes extrude hydrogel [47]. Solenoid microextrusion (Fig. 1C) utilizes electrical pulses to open a valve by
canceling the magnetic pull force generated between a floating
ferro-magnetic plunger and a ferro-magnetic ring magnet. A
similar configuration can be developed using a piezoelectricactuated system; however, it is not convenient for EBB while the
process mode is droplet [16].
2.2. Recent achievements using EBB
Several researchers have demonstrated EBB of tissue substitutes
in the literature. Different cell types have been loaded and deposited in a wide range of biocompatible hydrogels. Recently, Billiet
et al. used hepatocytes with gelatin methacrylamide hydrogel to
engineer artificial liver tissue constructs [48]. Cell viability after
th et al. demonstrated biodeposition ranged up to 97%. Horva
printing of lung tissue analogues for the first time [23]. The architecture of the air-blood barrier was very precise, comparable to
native tissue. Another group created lipid bilayers separating cellencapsulated droplets [49]. The functionalization of membrane
proteins caused the spontaneous creation and transmission of an
electrical current along defined pathways. With this advancement,
self-folding droplets can be used for isolating cancer cells from
healthy tissue or releasing cells for diagnostic applications in the
future. Melchels et al. performed a characterization of a new
gelatin-methacrylamide bioink containing gellan gum and
mannose [50]. They obtained various 3D structures (pyramid,
hemisphere, hollow cylinder) with high cell viability, where
hydrogel properties can be tailored by salt concentration. Another
group bioprinted human adipose tissue-derived mesenchymal
stem cells (hASCs) loaded in decellularized matrix components of
adipose tissue [51]. The bioink was printed in precisely-defined and
flexible dome-shape structures, and hASCs in bioprinted structures
showed significantly higher adipogenic differentiation than hASCs
cultured in non-printed decellularized adipose tissue matrix
components.
2.3. Comparison of EBB with other bioprinting techniques
The EBB technique has several advantages and disadvantages
with respect to other bioprinting techniques, including dropletbased bioprinting (inkjet-based [52], electrohydrodynamic jetting
[53,54] and acoustic-droplet ejection [55]) or laser-based bioprinting (stereolithography and its modifications [56], laserguidance direct writing [10] and laser-induced forward transfer
[57]). It has greater deposition and printing speed, which can
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
323
Fig. 1. EBB systems: (A) pneumatic micro-extrusion including (A1) valve-free and (A2) valve-based, (B) mechanical micro-extrusion including (B1) piston- or (B2) screw-driven and
(C) solenoid micro-extrusion.
324
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
facilitate scalability in a relatively short period of time. In addition,
the hardware is affordable and a wide array of bioprinting technologies is commercially available. In addition, EBB enables bioprinting a wide array of bioinks, including cell aggregates
[18,20,37,58], cell-laden hydrogels [59e62], micro-carriers [63]
and decellularized matrix components [64], while other techniques can only facilitate printing cell-laden hydrogels. Bioprinting
high cell density is currently feasible only with EBB technologies,
and the process is very biocompatible with reasonably small
process-induced cell damage and injury compared to other techniques. Moreover, the technology is easy to implement and can be
used by operators who have limited exposure to the technology.
The last and most important point is that EBB enables bioprinting
anatomically correct porous constructs [65], which is very challenging using other means (except for modifications of stereolithography [56]).
Despite its versatility and great benefits, EBB has some disadvantages when compared to other technologies. First of all, the
resolution of the technology is very limited; the minimum feature
size is generally over 100 mm [66], which is considerably lower than
the resolution in other bioprinting techniques [41]. Therefore, cells
cannot be precisely patterned and organized due to limited resolution. In addition, the bioink, in liquid or solegel state, should
possess shear thinning ability to overcome surface tension-driven
droplet formation in order to be extruded in the form of cylindrical filaments. Gelation and solidification requirements during the
extrusion process limits the hydrogels used in EBB. Furthermore,
shear stress on the nozzle tip wall induces a significant drop in the
number of living cells when the cell density is high [67]. The time it
takes to bioprint large constructs also affects cell viability. Bioprinting into cell culture media is not practiced, so cells are exposed
to dehydration and a lack of nutrients.
3. The bioink consideration
Extrusion-based bioprinting is very versatile in depositing a
wide array of bioink types, including hydrogels [60e62], microcarriers [63], tissue spheroids [18,20,37,58], cell pellet [68], tissue
strands [69] and decellularized matrix components [64], as shown
in Fig. 2. This versatility originates due to the larger nozzle diameter
ranges applied, the ability to deposit small building blocks in a
fugitive liquid delivery medium, flexibility in nozzle tip design and
the ability to extrude bioink in near solid-state. A general process
configuration is illustrated in Fig. 3A, where cells in the abovementioned bioink components can be loaded and extruded
through a microneedle.
3.1. Hydrogels
A wide variety of hydrogels have been experimented within
EBB. Depending on their crosslinking mechanism, hydrogels that
are applicable in EBB can be classified into three groups: physical
(temperature [70], and light [48]), enzymatic [71], and chemical
(pH [72], ionic compound [73]) crosslinking. Several review papers
have been published about hydrogels used in tissue engineering
[61,74]; thus, this paper focuses only on bioprintable hydrogels and
their applicability and performance in EBB. The reader is referred to
the paper by Ahmed et al. [75] for detailed information about a
wide variety of hydrogels.
Alginic acid, or alginate, is a polysaccharide derived primarily
from brown seaweed and bacteria. It is a family of natural copolymers of b-D-mannuronic acid (M) and a-L-guluronic acid (G).
Because of its biocompatibility, low price and fast gelation rate,
alginate has been widely used in EBB [76e78]. Different EBB systems have been experimented with due to the instant gelation
properties of the gel in ionic solutions of calcium (Ca2þ), such as
calcium chloride, calcium carbonate or calcium sulfate. These
mechanism are (i) bioplotting [14], (ii) bioprinting hydrogel with a
secondary nozzle using crosslinker deposition or a spraying system
[79], (iii) bioprinting using a coaxial nozzle-assisted system [80],
(iv) bioprinting pre-crosslinked alginate and further crosslinking it
thereafter [59] and (v) bioprinting alginate with an aerosol crosslinking process [81]. Although some researchers use the term
“bioplotting” and “bioprinting” interchangeably, there is a
misconception about the “bioplotting” term. In bioplotting
approach (see Fig. 3B1), cells in a hydrogel solution are extruded
into a plotting medium (crosslinker pool), where extrusion takes
place within the pool and the bioprinted scaffold stays inside the
pool until the process is completed. Therefore, extrusion of
hydrogels without a crosslinker plotting medium shall not be
classified under “bioplotting” approach. In bioplotting, the density
of the extruded bioink needs to be greater than that of the plotting
medium for successful deposition. By altering the temperature and
the viscosity of the plotting medium, extrusion and deposition
process can be controlled easily. In the second technique, shown in
Fig. 3B2, the crosslinker solution is deposited or sprayed (in large
liquid droplets) onto the bioprinted alginate using a secondary
nozzle, where the secondary nozzle can rotate around the primary
nozzle using a motorized system [82]. In the third technique (see
Fig. 3B3), alginate is bioprinted using a coaxial nozzle apparatus;
alginate is bioprinted through the core, and the crosslinker solution
is ejected through the sheath section of the outer nozzle, which is
slightly longer than the core nozzle, providing better control of the
extrudability of the bioink. Using a similar approach but an opposite configuration in coaxial nozzle development, alginate was
extruded for various applications such as creating multi-material
fibers for controlled drug delivery [83,84], bioprinting blood vessels [85] or microfluidic channels for tissue engineering applications [86] and encapsulating cell pellet to grow cell aggregates in a
strand shape [87]. In the fourth technique (see Fig. 3B4), precrosslinked alginate (with low crosslinker concentration) is bioprinted, providing a sufficient deposition quality of bioink and
structural integrity of the scaffold, followed by enhancing crosslinking by exposing the bioprinted scaffold to a high concentration
of crosslinker solution. In this approach, the mechanical properties
of printed constructs are better, but the pressure level for the
extrusion process is higher relative to the density of the precross
linked hydrogel. In addition, the bioink is not even, which brings
discontinuities and nonuniformities during extrusion. In the fifth
approach, shown in Fig. 3B5, alginate is bioprinted onto a stage,
where the crosslinker solution is fumed over the entire bioprinting
space using an ultrasonic humidifier. The difference between the
fifth and the spraying approach is that fuming process generates
highly small particles of the crosslinker solution in near vapor state
that can be uniformly distributed over the entire structure as
oppose to the spraying approach. This enables simultaneous
crosslinking between layers, generating mechanically and structurally integrated constructs. All these approaches have pros and
cons, but it has been demonstrated that bioprinting pre-crosslinked
alginate or using a coaxial nozzle-assisted cross-linker deposition
system shows promising results in terms of printing accuracy and
the ability to 3D bioprint tissue structures with well-integrated
interlayers [80]. Despite these advantages, cells are unable to
interact with the biomaterial matrix via cell surface receptors due
to the strongly hydrophilic nature of alginate. Cells in alginate are
quite immobilized and have limited proliferation and interaction
capabilities. In addition, mechanical properties are limited when
low concentration is used, which favors higher cell viability and
proliferation capabilities. Besides, cells cannot adhere easily unless
surface modifications are applied. Thus, researchers attempted to
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
325
Fig. 2. Bioink types used in EBB: (A) cells loaded in hydrogels, (B) polymer micro-carriers pre-loaded with cells [63], (C) tissue spheroids made of cells and ECM [21], (D) cell pellet
in nozzle tip [41], (E) tissue strands [29] and (F) dECM before loading cells [51].
modify alginate using cell adhesion ligands containing the
arginine-glycine-aspartic acid (RGD) amino acid sequence [88],
collagen type I [89] or oxygenation [77], enabling significant
improvement in cell adhesion, spreading and proliferation.
Chitosan is produced by deacetylation of chitin and it is well
known for its non-toxic, biodegradable, antibacterial and antifungal
properties and is used, for example as wound dressing [90]. Chitosan hydrogels are widely used in bone, skin, and cartilage tissue
engineering, due to the analogous content of hyaluronic acid and
glycosaminoglycans as in native tissue [91e94]. The shortcomings
of chitosan are its slow gelation rate (up to 10 min after injection)
and low mechanical properties; only highly viscous samples are
able to hold the shape by themselves for several hours [94,95].
These limitations can be eliminated by blending chitosan with
other hydrogels to strengthen it and gain control over its polymerization rate. Chitosan is dissolved in acid solutions and then
crosslinked by ionic and covalent agents. Recently, a water-soluble
form at neutral pH ranges was obtained with a gelation capability at
about 40 C [96]. Using EBB, chitosan has been used in the fabrication of various scaffolds, such as microfluidic, perfusable channels [86], scaffolds with embedded adipose stem cells that
successfully underwent chondrogenesis [97], and 3D printed scaffolds in order to study the inflammatory response of an organism
[24]. Some of the bioprinting mechanisms presented in Fig. 3B1e5
can also be applied in the bioprinting of chitosan hydrogel.
Gelatin is a fibrous protein, obtained by partial hydrolysis of the
triple helix structure of collagen into single-strain molecules [98].
Gelatin has good biocompatibility, high water-adsorbing ability and
non-immunogenicity, and it is completely biodegradable in vivo
[99]. Gelatin is a thermally reversible hydrogel, which is solid at low
temperatures, with low mechanical properties and instability under physiological conditions. For EBB applications, various chemical
and physical cues, such as metal ions or glutaraldehyde, have been
used to improve its bioprintability and stability in physiological
conditions [100,101]. In order to obtain a photopolymerizable
hydrogel that is stable at 37 C, gelatin was chemically modified
with methacrylamide side groups. Crosslinking of the
methacrylamide-modified gelatin was performed in the presence
of a water-soluble photoinitiator [102]. The resulting gelatin
methacrylate composite hydrogel (GelMA) was easily extruded
through a pneumatic dispenser equipped with a UV-light source
[25,48] as shown in Fig. 3C. The printability of GelMA is dependent
on gel concentration, UV time exposure and cell density, and the
duration and intensity of UV curing can affect cell viability,
hydrogel density and stiffness [25,48]. Furthermore, temperaturesensitive gelatin has been used as a sacrificial material to fabricate 3D printed scaffolds with open fluidic channels [103]. Upon
printing, gelatin can be liquefied after incubating the scaffold at
37 C, leaving empty and perfusable channels. Such structures
containing fluidic networks enable the flow of culture medium,
oxygen and drugs throughout the constructed scaffold, promoting
cell survival and functions in the long term.
Hyaluronic acid (HA), also known as hyaluronan, is a natural
nonsulfated glycosaminoglycan ubiquitous in almost all connective
tissues [104]. Hyaluronic acid has been extensively used in clinics as
a dermal filler and have lubricating properties as synovial fluid in
loss function and pain-causing changes in articular joints [105].
During early embryogenesis, HA can be found in high concentration, and it has a crucial role in the regulation of cell behavior and
functions such as movement, proliferation and angiogenesis. The
tunable physical and biological properties of HA-based hydrogels
make them an attractive material for 3D bioprinting applications.
Hyaluronic acid is the major tissue ECM component of cartilage.
Three-dimensional printed chondrocyte-encapsulated HA hydrogel
showed high viability compared to cells in collagen hydrogels [106].
However, HA has poor mechanical properties and is characterized
by rapid degradation [107]. Enhancement of these properties to
control the degradation rate is possible by chemical modification.
By itself, HA does not have suitable features for EBB because of the
abovementioned limitations. Nonetheless, it can be functionalized
with UV-curable methacrylate (MA), since crosslinking is easily
controlled with the time of photopolymerization [108]. The
HAeMA keeps its crucial biological properties because of the
enhanced mechanical properties given by methacrylate and by
326
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
Fig. 3. Processes configurations for various bioink materials: (A) bioprinting cells in hydrogel-based bioink, (B1) bioplotting hydrogel bioink into a crosslinker reservoir, (B2)
crosslinker deposition or spraying system, (B3) coaxial-nozzle system, (B4) bioprinting pre-crosslinked bioink, (B5) aerosol crosslinking system, (C) UV-integrated system, (D1) a
heating-unit assisted barrel with cooling-unit assisted bioprinting stage, (D2) a cooling-unit assisted barrel with a heating-unit assisted nozzle tip, (E) multi-chamber single nozzle
system, (F) bioprinting micro-carriers (pre-loaded with cells) that can be extruded in hydrogels as a delivery medium, (G1) extrusion of tissue spheroids in a fugitive cell-inert
hydrogel into a support mold for fusion and maturation of spheroids, (G2) bioprinting pre-aggregated cell pellet into a support material that is inert to cell adhesion, (G3) bioprinting tissue strands directly without using delivery medium or support mold, and (H) bioprinting dECM within printed PCL frame to mechanically support gelation of dECM.
using a UV-integrated system as presented in Fig. 3C. It is a suitable
hydrogel for EBB with high printability capacity [45,61,109,110].
Another noteworthy co-hydrogel is poly(ethylene glycol), in which
flexible chains provide elasticity and HA chains provide mechanical
strength [107].
Poly(ethylene glycol) (PEG) or poly(ethylene oxide) (PEO) is
widely used as an excipient in medicines and in nonpharmaceutical products [111e113]. The PEG-based hydrogels are
biocompatible with reduced immunogenicity, are FDA approved
(used in enzymes, i.e., mPEG per adenosine deaminase, mPEG-Lasparaginase and pegloticase; cytokines, i.e., pegloticase and
peginterferon alfa-2b; and growth factors i.e., pegfilgrastim, pegvisomant and methoxy polyethylene glycol-epoetin beta [114]) for
internal use and can be crosslinked using physical, ionic or covalent
crosslinks [115]. Photopolymerization of PEG-based hydrogels with
tunable mechanical properties has attracted considerable attention
in EBB systems. Using a UV-integrated system (as shown in Fig. 3C),
Hockaday et al. used a photocrosslinkable polyethylene-glycol
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
diacrylate (PEG-DA) for rapidly 3D printing of complex, mechanically heterogeneous and clinically sized aortic valve scaffolds.
Scaffolds were seeded with porcine aortic valve interstitial cells and
cultured for up to 21 days [116]. However, cells adhered on the
surface of the scaffolds did not show any sign of spreading or
proliferation, which makes PEG a good candidate for cell encapsulation vehicles, although it requires functionalization for
culturing on the surface of scaffolds. The immobilization of cell
adhesion sites and growth factors during the bioprinting process
promotes cell proliferation and migration and tissue regeneration
[117,118].
Agarose is a galactose-based polymer material extracted from
seaweed. Agarose hydrogel has thermosensitive and thermoreversible properties. A few different types of agarose are available in the
market, depending on the hydroxyethylation that directly affects
the melting temperature of agarose [119]. The most suitable
agarose for EBB is low-melting- and low-gelling-temperature
agarose, which is easy to liquefy and gels at 26e30 C [120],
where gelation also depends on agarose concentration. In Ref.
[121], it was shown that agarose was cytocompatibile, supports
differentiation of hASCs, had suitable abilities for 3D cell encapsulation and had stable mechanical properties that mimic native
cell niche. However, DNA, protein and proteoglycan biosynthesis of
hASCs in Matrigel was significantly lower than that in alginate or
gelatin hydrogels. An EBB configuration presented in Fig. 3D1 can
be used to bioprint low-melting-temperature agarose, where
extruded agarose in liquid state rapidly solidifies when bioprinted
onto a freezing stage. Campos et al. showed 3D bioprinted
mesenchymal stem cells encapsulated in agarose hydrogel, where
the entire construct was supported by fluorocarbon [122]. Cells
were deposited to create tubular structures with almost 100% cell
viability after 21 days. Because of the abovementioned properties,
agarose is also very suitable for developing 3D cell-culture platforms, acting as a non-adhesive hydrogel for formation of cell aggregates and supporting cell aggregation due to its cell adhesioninert nature [21,123,124].
Collagen type I has been used extensively in tissue engineering
as a growth substrate for 3D cell culture or as a scaffold material for
cellular therapies [125]. Collagen type I molecules contain the
amino acid sequence RGD binding to integrin receptors [126],
which mediate the interactions between the cytoskeleton and ECM
and serve as signal transducers, activating various intracellular
signaling pathways and cell functions. Acid-soluble collagen molecules are crosslinked when the pH, temperature and ionic strength
are adjusted to near physiological values. Once neutralized at a pH
ranging from 7 to 7.4, collagen polymerizes within 30e60 min at
37 C [106], which makes it a good candidate for in situ bioprinting
applications. The mechanism of collagen crosslinking is also suitable for in vitro EBB studies. It is ideal for the bioprinting process
taking place when collagen starts polymerization. Extruded
collagen is then incubated until full crosslinking is achieved. The
printability feature was demonstrated as far back as 2004 by Smith
et al. [72], where collagen type I containing bovine aortic endothelial cells (BAECs) was bioprinted using a pneumatic-driven EBB
system. Although a configuration presented in Fig. 3D2 is used to
bioprint collagen, where the bioink is kept in ice-cold temperature
ranges and heated up to physically relevant temperature ranges,
full crosslinking of collagen can be achieved in 30 min in incubation
after bioprinting. Collagen type I was successfully 3D printed in
combination with different cell types and in combination with
natural or synthetic materials to enhance the bioprinting capability
and the mechanical properties of native collagen [127]. Although
collagen type I has some disadvantages, such as sensitivity to
metalloproteinases and poor mechanical properties [128], it has
been successfully used as a major biomaterial supporting other
327
hydrogels such as fibrin [129].
Pluronic® is a tri-block copolymer based on poly(ethylene
glycol)-block, poly(propylene glycol)-block, and poly(ethylene
glycol) (PEO-PPO-PEO) sequences. Pluronic has been approved by
the Food and Drug Administration (FDA) and is used as a drug
delivery carrier and as an injectable gel, in the treatment of burns
and in other wound-healing applications [130,131]. The temperature sensitivity of Pluronic is based on the intermolecular association of PPO blocks leading to the formation of micelle structures
above critical micelle temperature. For example, a 20% Pluronic F127 solution is sol at room temperature and gels above 20 C; the
solegel transition can be modified by changing the solution concentration [110]. F-127 has great potential in the EBB process
[130,132] but requires a special bioprinting apparatus. Thus, a
thermally controlled nozzle system is required to solidify the bioink
as extrusion takes place as presented in Fig. 3D2. When the bioink is
loaded into the barrel in a liquid state, it is kept at low temperature
using a cooling chamber if the melting temperature is below room
temperature. A heating unit around the dispensing tip enables
precise control of the temperature while the bioink is extruded. In
this way, the bioink can be extruded in solid filament form.
Optionally, a heating plate can be used to prevent melting of the
hydrogel and loss of the structure and shape. Using Pluronic,
spatially well-defined constructs can be printed accurately [72].
Despite its great benefits, F-127 has very weak mechanical and
structural properties and possesses quick degradation as well as
rapidly dissolving in aqueous solutions. Therefore, it can be
considered chemically modified by blending with other polymers
to improve the physical and mechanical properties of the resulting
copolymer. Researchers have considered Pluronic F-127 as a sacrificial material (either considered a fugitive ink [132]) or a support
material [133] to create a vascular network as discussed in details in
Section 5.
Matrigel is a gelatinous protein mixture produced by mouse
Engelbreth-Holm-Swarm sarcoma cells. One of its biggest advantages is promoting the differentiation of multiple cell types and
outgrowth from tissue fragments [134]. Matrigel has been extensively studied as a candidate for cardiac tissue engineering [135].
Research results of Fedorovich et al. revealed that Matrigel promoted vascularization faster than Pluronic, alginate and agarose
hydrogels [136]. Matrigel is a thermosensitive material but is not
reversible. Once it crosslinks at 24e37 C, it does not decrosslink
when cooled. Gelation takes about 30 min and starts above 4 C in
the barrel, where the gelation time depends on the concentration
as well. In order to extrude Matrigel, it is necessary to possess a
temperature-controlled bioprinting system (as presented in
Fig. 3D2) to retain the hydrogel at 4 C. Otherwise, the dispensing
needle clogs and makes bioprinting very challenging. In the literature, the bioprinting of Matrigel demonstrated high viability of
human epithelial cells [39]. Furthermore, 3D bioprinted bone
marrow stromal cells in Matrigel showed higher survival rate than
those in alginate or agarose hydrogels, up to 7 days [136]. Multicellular constructs were also extruded and implanted for bone
regeneration, and vascularization by the host tissue was demonstrated 2 weeks after implantation [137].
Methylcellulose (MC), a chemical compound derived from
cellulose, is a semi flexible linear chain of polysaccharide and has
the simplest chemical composition among cellulose products
[138]. It is a thermosensitive and thermoreversible hydrogel, with
solegel transition depending on polymer concentration, molecular
weight and dissolved salt [139]. The aqueous MC solution used for
cell culture is capable of gelling below 37 C [140]. A derivative of
MC, silanized hydroxypropyl methylcellulose hydrogel, has been
patented due to pH-sensitive properties and used for 3D osteogenic and chondrogenic cultures [141,142]. Methylocellulose is
328
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
bioprintable, although it requires an additional apparatus as
demanded by other thermosensitive and thermoreversible
hydrogels, including a thermally controlled nozzle system (as
presented in Fig. 3D2) and a heating plate. Methylocellulose is not
appropriate for long-term culturing of cells. It presents unstable
character with partial degradation immediately after being
exposed to cell culture media [140]. Methylocellulose with
bioactive glass was 3D printed with tremendous mechanical
strength and can be an exceptional candidate for bone regeneration [143]. Recently, EBB was used to print nanofibrillated cellulose blended with alginate and loaded with chondrocytes [144]. In
addition to EBB uses, methylcellulose was demonstrated as a
scaffold matrix in the fabrication of spheroids made of corneal
stromal cells cultured in a serum-free medium under a static and
rotary cell culture system that can be used for further bioprinting
applications [145].
Fibrin has been widely used in tissue engineering due to its
inherent cell-adhesion capabilities and high cell seeding density
[26,146,147]. It has simple gelation properties via directly
combining fibrinogen, Ca2þ and thrombin in room temperature. Its
polymerization conditions might be optimized depending on cell
spreading properties or desired stiffness ranges, which is manipulated by concentration adjustment. Despite its great biological
properties, fibrin has some limitations, such as a rapid degradation
rate and limited mechanical stiffness. Fast and irreversible gelation
causes difficulties during the extrusion process, which does not
facilitate stable structures after extrusion [62]. There are a few
methods applied in EBB. First of all, two components of fibrin
(fibrinogen and thrombin) are very suitable for inkjet printing
when printed separately [148,149] and theoretically can be
extruded as well. In the second approach, fibrinogen and thrombin
can be mixed on ice preventing gelation and then extruded using a
configuration presented in Fig. 3D2. The third method is using a
multi-chamber, single-nozzle apparatus that blends both fibrinogen and thrombin into one solution at the very end of the extrusion process [71] as shown in Fig. 3E. In the fourth method,
fibrinogen can be blended with another hydrogel, extruded in a
desirable pathway and then crosslinked with thrombin [150]. Fibrin
also has great potential in in situ bioprinting applications [151]
because printed fibrinogen can rapidly crosslink with naturally
occurring thrombin in situ.
In addition to bioprinting a single type of hydrogel, the multichamber, single-nozzle configuration shown in Fig. 3E has been
used to blend and print multiple hydrogels or the same hydrogels
with different material properties to generate heterogeneity in
extruded fibers with varying properties of the material along the
longitudinal direction of filaments [152]. Using a nozzle assembly
shown in Fig. 3E, biofabrication of hybrid tissue-engineered porous
scaffolds have been demonstrated, where multiple functional
properties can be obtained by changing biomaterial type and
concentration spatially [153]. Material flow and concentration
through the mixture chamber can be controlled by regulating
positive nozzle pressures. A similar approach was extended to triple chambers in a recent report [154], where scaffolds were fabricated by bending materials, chitosan, sodium alginate and chitin
powder using a static mixer nozzle mounted on a 6-axis robotic
printer.
Hydrogels in general lack the suitable biomimicry for the bioprinted cell phenotype, while each hydrogel does not include all
the proteins existing in the corresponding cell-specific ECM. In
addition, loading cells in high cell-density ranges close to those of
natural tissues is challenging. In general, the higher the cell density, the better the cells interact and form the tissue [155]. Cell-tocell interactions are not just lessened due to limited cell density;
the microstructural environment of the hydrogels does not allow
cells to interact efficiently. Hydrogels such as gelatin and collagen
or RGD peptides have fibrous microstructural environments that
allow cells to spread easily. However, other hydrogels do not
possess this feature, and cells in general do not spread and do
remain rounded. Concentrations of hydrogels also trigger this
issue, creating a trade-off conflict between biological and mechanical properties. The higher the concentration of hydrogels, the
lower the mobility of the cells in them and the higher the mechanical properties. Mechanical properties, on the other hand, are
required to preserve the printed cell-laden scaffold intact. Some
gels such as Pluronic F-127 can preserve their integrity when they
are cultured in bulk; however, they cannot preserve their mechanical integrity when printed in filaments, and they dissolve in
culture media quickly. Thus, strong gelation is needed before
culturing cells in hydrogels. Rheological properties of hydrogels
also play crucial roles in the EBB process, while bioink suspension
should overcome surface-tension-driven droplet formation and be
drawn in the form of straight filaments. When hydrogels are used
in low concentration in the bioink, their drawability in the form of
a straight filament is limited because the bioink spreads very
quickly. On the other hand, when they are loaded in very high
concentration, their extrusion process is very challenging and
needs a significant level of pressure. Although this seems to be
feasible for the process, it harms the cells significantly due to
increased shear stress.
Degradation of hydrogels and associated byproducts are other
limitations in hydrogel-based bioinks. In general, hydrogels
degrade very slowly in vitro compared to in vivo; thus, cells that are
encapsulated in them cannot proliferate and deposit considerable
amounts of ECM. On the other hand, if degradation time in vivo is
too long, it causes a chronic inflammatory response. Also, hydrogels
should be chosen carefully because the toxic byproducts of degradation can be harmful to cells. In summary, hydrogels must be
matched with the type of regenerated tissue, and they should
require support for cells until the completion of the tissue regeneration process. Time of degradation is different for every type of
hydrogel. For example, Yu et al. injected alginate and fibrin into rats
[156]. After five weeks, alginate was still identified, whereas fibrin
was reabsorbed.
Table 1 summarizes the hydrogels used in EBB, including the cell
types used, their crosslinking mechanisms, the reversibility of their
physical state, their extrusion mechanisms, their advantages and
disadvantages and the sample tissue constructs that were bioprinted using EBB.
3.2. Micro-carriers
Recently, micro-carriers (Fig. 2B) have been used as reinforcement blocks in the EBB process. Cells can be loaded into small
carriers in different geometries (spherical in general [157]) with
porous architecture. Commercially available micro-carriers for
bone and cartilage regeneration are made with dextran [158,159],
plastic [160,161], glass [158], gelatin [63,162] and collagen
[163,164]. When cells are cultured on them, they allow cells to
quickly proliferate. Maturated micro-carriers can be printed in a
delivery medium such as hydrogels, as shown in Fig. 3F. One of the
previously described hydrogel crosslinking mechanisms can be
used during bioprinting of micro-carriers. It was demonstrated in a
recent article that cells can have better interaction and aggregation
inside the micro-carriers than the cells loaded in the hydrogel solution alone [63].
Micro-carriers have great potential in the scale-up tissue
printing process using hard polymers. In general, hard polymers are
not convenient for encapsulating cells due to limited diffusion;
however, making porous micro-carriers and loading cells and
Table 1
Hydrogels used in EBB.
Crosslinking Solidification EBB system Advantages
mechanism reversibility
in EBB
Hydrogel type
Bioink
Alginate
Ionic
Aggregates, proteins,
encapsulated cells (skeletal
myoblasts, BMSC, SMC,
MSC, ASC, CPC,
chondrocytes,
cardiomyocytes)
Pneumatic
microextrusion
and
bioplotter
Disadvantages
Sample tissue construct
Biocompatibility, good extrudability Low cell adhesion and
and bioprintability, fast gelation, good spreading without
modification of hydrogel
stability and integrality of printed
construct, medium elasticity, low cost,
nonimmunogenic
Ref.
[31,34,66,86,136,172,222,223]
Reproduced/adapted with
permission from Ref. [31],a
Pneumatic
microextrusion
Collagen type I Encapsulated cells (bovine pHmediated or
aortic endothelial cells,
keratinocytes, fibroblasts, thermal
rat neural cells, MSC, AFS)
Cell-adherent, promote proliferation, Poor mechanical properties,
signal transducer, good extrusion and slow gelation, unstable
bioprinting abilities,
nonimmunogenic
[32,70,72,103,127,129,224,225]
Gelatin
Encapsulated cells (HepG2, Thermal
hepatocytes, fibroblasts,
SMC)
þ
Mechanical Cell-adherent, biocompatibile,
and
nonimmunogenic
pneumatic
microextrusion
Unstable, fragile, weak
mechanical properties at
physiological temperature and
low abilities to extrude and
print without modification
[25,48,66,101,103,226]
Reproduced/adapted with
permission from Ref. [25],a
PEG
Encapsulated cells (bone
marrow stem cells or
porcine aortic valve
interstitial cells)
Ionic,
physical, or
covalent
agents
Pneumatic
microextrusion
Support cell viability,
biocompatibile, nonimmunogenic,
widely used in tissue engineering
when modified
Low proliferation rate, low cell
adhesion, weak mechanical
properties and stability
without modification
[116,136]
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
Reproduced/adapted with
permission from Ref. [103],a
Reproduced/adapted with
permission from Ref. [116],a
Fibrin
Acellular scaffolds or
encapsulated cells (AFS,
HUVEC)
Enzymatic
Pneumatic
microextrusion
Difficult to control geometry,
Promote angiogenesis (causes
inflammatory response), fast gelation, low mechanical properties,
limited EBB printability
good integrality, medium elasticity
[71,129,150,197]
Image courtesy of Prof. Hosek
(continued on next page)
329
Hydrogel type
Bioink
330
Table 1 (continued )
Crosslinking Solidification EBB system Advantages
mechanism reversibility
in EBB
Disadvantages
Sample tissue construct
Ref.
from Czech Technical
University in Praqueb
Matrigel
Encapsulated cells (HepG2, Thermal
BMSCs, gMSC, gEPC)
Pneumatic
microextrusion
Promote cell differentiation and
vascularization of construct, support
cell viability, good bioprintability,
highly suitable particularly for cardiac
tissue engineering
Slow gelation, which affects
mechanical stability, require
cooling system for EBB,
expensive
[39,136,137]
Reproduced/adapted with
permission from Ref. [39],a
Encapsulated cells (BMSCs Thermal
osteosarcoma cells, MSC)
þ
Pneumatic
and
mechanical
microextrusion
High mechanical properties, stable,
resistant for protein adsorption, low
cost, good integrality,
nonimmunogenic
Low cell adhesion, fragile,
require heating system for EBB
[70,122]
Reproduced/adapted with
permission from Ref. [122],a
Chitosan
Pneumatic
microextrusion
Acellular scaffolds,
Ionic or
encapsulated cells
covalent
(cartilage progenitor cells, agents
MSC, CPC)
Antibacterial and antifungal, medium Weak mechanical and stability
printability, nonimmunogenic
properties without
modification, slow gelation
rate
[70,86,96,97]
Reproduced/adapted with
permission from Ref. [97],a
Pluronic® F-127 Encapsulated cells (human Thermal
primary fibroblasts, BMSC,
HepG2)
þ
Pneumatic High printability, good bioprintability,
nonimmunogenic
and
mechanical
microextrusion
Poor mechanical and structural
properties, slow gelation, rapid
degradation, require heating
system for EBB
[72,132,136,227]
Reproduced/adapted with
permission from Ref. [132],a
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
Agarose
Reproduced/adapted with
permission from Ref. [144],a
a
All samples figures are reprinted with permission from the respective publishers as indicated in the reference source.
Image courtesy of the author.
3.3. Cell aggregates
b
Low bioprintability, sensitive
on common cell culture media,
unstable
Methylcellulose Encapsulated chondrocytes Thermal,
pHmediated
þ
Mechanical High printability, nonimmunogenic
microextrusion
Reproduced/adapted with
permission from Ref. [228],a
Rapid degradation, poor
mechanical properties and low
stability without modification
Pneumatic Promote proliferation and
angiogenesis, fast gelation, good
and
mechanical bioprintability, nonimmunogenic
microextrusion
Ionic,
covalent
agents
Hyaluronic acid Encapsulated cells
(chondrocytes, HepG2,
C3A, fibroblasts)
331
allowing them to proliferate in them would be a great approach to
assembling these carriers in 3D for hard-tissue scaffolding applications such as bone or cartilage. Although they can be considered
an intermediate stage between hydrogels and cell aggregates,
micro-carriers still have some challenges associated with them. The
major limitations of this technique are how to deliver them successfully to the bioprinting stage and how to assemble them in 3D.
In general, hydrogels are used as delivering mediums as in the
tissue spheroid case, but ensuring contact between micro-carriers
is very difficult. Other limitations are degradation of the microcarrier material and associated end products that can be toxic to
cells, and risks of clogging of nozzle tip due to the hard and adhesive nature of the micro-carriers, which can trigger their aggregation inside the nozzle tip.
[144]
[45,109]
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
Scaffold-free cell aggregates have been considered a promising
direction in bioprinting because they enable building tissues in a
relatively short period of time compared to the commonly used
cell-laden hydrogel approach. Instead of expecting cells to proliferate in hydrogels, one can start with extremely high cell numbers,
triggering them to deposit ECM in a confined space per demand,
such as cylinder, torus, spheroids and honeycomb [19,37,165]. The
hydrogel-free nature of the biomaterial facilitates quick maturation
of building blocks, and the technology has demonstrated fabrication of cardiac patches [166,167], blood vessels [21] and nerve tissues [68]. Several biofabrication approaches have been investigated
in the literature for cell aggregates, particularly tissue spheroids.
These methods include the hanging drop, pellet (re-aggregation)
culture or conical tube, micro-molded (non-adhesive) hydrogels,
microfluidics (hydrodynamic cell trapping), liquid overlay, spinner
flask and rotating wall vessel techniques [168]. It should be noted
that not all of them have been applied in fabricating spheroids for
bioprinting purposes, but any of them can be considered as an
alternative approach as long as the technique facilitates efficient
and economical generation of spheroids for scale-up tissue-printing activities. Not just homocellular, but also heterocellular, examples have been demonstrated [169e171]. Despite their great
advantages, tissue spheroids have several challenges during the
EBB process. First of all, loading tissue spheroids into the nozzle,
which is generally a pipette [20] (see Fig. 3G1), is quite difficult.
Tissue spheroids need a delivering medium to be extruded; in this
case, the delivering medium is a fugitive ink such as a thermosensitive hydrogel that is inert to cell adhesion. In addition, tissue
spheroids have quick fusion capabilities that trigger their aggregation inside the nozzle tip and make their printability very challenging. Upon printing, there is also a risk that tissue spheroids may
not contact each other tightly enough. This generates a gap between spheroids, and the resulting tissue will be leaky. Last, and the
most important, fabricating a huge number of tissue spheroids and
bioprinting them in an automated way for long bioprinting missions is another hurdle to be faced when considering the transition
of the technology to scale-up tissue fabrication in the near future.
Despite these challenges, bioprinting tissue spheroids has been an
exemplary means to rapidly create tissues in vitro, and further
modifications have been made to the technology. Instead of delivering cells in high density in aggregated mature spheroid form,
delivering them directly in pellet form works more efficiently [155],
as shown in Fig. 3G2. In that case, bioprinting cells into printed
micro-molds is essential to confine cells inside the molds and
trigger them to aggregate in the shape of the molds [172]. Thus, two
materials need to be deposited into the construct, where a cell
pellet can be printed inside hydrogels that are inert to cell adhesion,
such as agarose or alginate. There is a controversy among some
332
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
scientists about whether or not the applied molding approach
should be considered a scaffold. Although the mold itself supports
the tissue to grow and mature, cells do not use the mold matrix to
proliferate through; thus, the applied mold can be considered as a
support structure, which is very common in traditional additive
manufacturing technologies [22] used for supporting overhangs.
The major hurdle with this approach is the difficulty of making
large-scale tissues without using a temporary molding material.
Thus, tissue strands [173] (Fig. 3G3) can be considered as an alternative approach, where long strands of tissues can be fabricated
and printed using a custom-made nozzle apparatus. In this case, the
laborious nature of the spheroid preparation and loading can be
eliminated, and the need for printing an enclosure mold can be
eliminated for cell pellets. Although this approach provides the
unique advantage of printing tissue strands in tandem with
vasculature, increasing the size of the tissue strands or the need for
neo-capillarization in them can be considered milestones on the
way to generating larger-scale tissues and organs in the future
[29,69]. Despite the great advantages of the scaffold-free approach,
the majority of the research community prefers hydrogel-based
bioink due to its simplicity, abundance, scalability, affordability
and ease of bioprintability, as well as the fact that there is no need
for huge cell numbers to start with.
Cell-aggregate-based bioinks have great advantages, such as
better cellular interactions, including homocellular and heterocellular interactions; close biomimicry; quick tissue formation; and
long-term stability of cell phenotypes in 3D [155]. Despite these
advantages, they have several limitations. First of all, a very high
number of cells is needed to prepare a sufficient amount of aggregates. These numbers can go up to a few hundred million cells
depending on the cell size and how quickly they deposit ECM. In
general, expanding cells in these numbers is labor-intensive and
costly, and some cell types cannot grow quickly, which limits their
applicability and availability. In addition, parenchymal cells in
highly metabolic organs do not secrete many ECM components,
and the resulting cell aggregates are very weak in mechanical and
structural integrity [174]. Therefore, stromal cells should be
cocultured to provide enough strength for bioprinting uses. In
addition to mechanical properties, the dimensional constraints are
another hurdle. In general, the permeability of cell aggregates is
smaller than that of hydrogels, and the diffusion of media and
oxygen is highly limited. Thus, fabrication of spherical aggregates
over 400 mm can induce hypoxia, which is hard for highly metabolic cells to survive [175]. Resilient cells (i.e., stromal cells) or cells
that like hypoxia (i.e., chondrocyte) can surpass these limitations.
One of the naturally occurring spheroids in the human body is the
lymph node. This tissue comprises stromal cells such as endothelial cells, fibroblasts and follicular dendritic cells, which provide
physiological functionality in tissue ranging from a few millimeters
to 1e2 cm long [176]. Thus, neocapillarization inside the cell aggregates is highly desired for scale-up fabrication of tissues and
organs. Ehsan et al. presented vascularized tumor spheroids [26].
Early stages of tumor progression were investigated, and their
work stands as a great example of a vascularized threedimensional in vitro tissue model, which can be used for creating
other organoids. From a bioprinting standpoint, bioprinting cell
aggregates is very trivial when the cell pellet is loaded in the preaggregated state (Fig. 3G2) while the bioink can be printed like a
hydrogel-based bioink without need for any other means. In that
case, a supporting mold structure is needed for cells to aggregate.
The mold structure should be printed with a minimum mold
cavity; otherwise, cell pellets do not form aggregates, but rather
remain a cell suspension [177]. For scale-up tissue printing missions, the need for molding is thus not ideal. When cell aggregates
are loaded in mature form such as tissue spheroids or strands
(Fig. 3G1), printing is not trivial while the bioink (in solid state)
should be transferred to the printing stage with minimum stress
on the cells. Thus, hydrogels or biological oil can be used as a
medium to deliver them on the bioprinting stage; however, such a
medium brings an issue when it needs to be washed out from the
printed construct. In general, cell aggregates need to be printed
before they become fully maturated, such as in the first 10 days of
cell aggregation. Otherwise, maturated cell aggregates lose their
ability to fuse.
3.4. Decellularized matrix components
In addition to recent advances in hydrogel-free approaches, the
extracellular matrix that is derived from nature's own scaffold has
been considered as a new bioink source for advanced tissue fabrication. Taylor's groundbreaking work in organ decellularization
[178] has attracted numerous researchers in the last five years in
the regeneration of organs such as the heart [179], kidney [180],
liver [181], cartilage and bone [182], pancreas [183] and others
[7,184]. This later inspired Dong-Woo and his coworkers [64] to use
decellularized matrix (dECM) components in printing tissue analogues. In their recent study, they decellularized tissues and
chopped them into smaller fragments, which were then loaded
with cells and printed with a PCL frame to support the tissue analogues. The process is illustrated in Fig. 3H. Three different cells
types, including hASCs, human inferior turbinate-tissue derived
mesenchymal stromal cells (hTMSCs) and rat myoblast cells, have
been tested using the proposed technology and demonstrated the
natural differentiation of cells when they were loaded in their
native dECM.
The approach seems to have a great benefit for biomimetic tissue and organ printing when the dECM bioink compounds can be
tuned in a way that allows them to be printed with enhanced
mechanical properties without the need for a polymer frame for
future studies [51]. Decellularization matrix components, on the
other hand, have limitations associated with the maturity state of
the technology. Since dECM-based bioink has not yet been well
established, there are some limitations related to the need for
protocols and the low abundancy and the affordability of the bioink. Since the dECM is obtained from the decellularization of the
natural organs and tissues, and the resultant dECM is tiny when the
deceullarized dECM is crushed into small pieces, a very large volume of initial tissues or organs is needed to create scale-up tissues
after bioprinting. In addition, dECM loses its mechanical and
structural integrity as well as some biochemical properties when it
is crushed into very small fragments. Furthermore, some toxic residuals can still stay in the crushed dECM components. Due to these
issues, printed bioink cannot facilitate cell formation while cells can
absorb the matrix components or the matrix shrinks significantly.
Since the mechanical properties are very weak, there is a need for a
frame printed using a hard material to keep the dECM structure
without letting it collapse.
4. Extrusion-based bioprinters
The first EBB technology, 3D plotting of thermo-reversible gels
in a liquid medium, was reported by Muelhaupt's group at Freiburg
Materials Research Center in the early 2000s [120]. The technology,
named bioplotter, was later commercialized by EnvisionTec as 3DBioplotter®. Since then, a number of extrusion-based bioprinters
have been demonstrated by several research groups; some of them
have been commercialized. The ideal bioprinter has specific system
requirements, which include high resolution and accuracy, highdegree-of-freedom motion capability and motion speed, the ability to dispense various biomaterials simultaneously, user-
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
friendliness, compactness, full-automation capability, sterilibility,
affordability and versatility [41]. Several extrusion-based bioprinters have been developed in the literature. Some notable ones
include a 3D printer with three heads enabling bioprinting of blood
vessels and cardiac tissue constructs, developed by Forgacs and his
coworkers [185], the Palmetto printer with the capability to
dispense tissue spheroids, developed by Medical University of
South Carolina (MUSC) and Clemson University [77], a multi-head
tissue/organ building system (MtoBS) possessing six dispensing
heads to fabricate heterocellular tissue constructs (i.e., osteochondral tissue), developed by Jin et al. [186], and a Multi-Arm BioPrinter [80] enabling bioprinting of hybrid constructs (scaffoldbased and scaffold-free bioink materials) using independent robot
arms in tandem.
Until 2005, 3D printers, in general, were expensive, proprietary
and in industrial scale, and their high cost and closed nature limited
the accessibility of the technology to researchers. With the invention of the Fab@ Home printer [187], the first open-source low-cost
printer was available to the public with versatile and multimaterial printing capabilities that accelerated technology innovation and its migration into the bioprinting space. The emergence of
commercially available bioprinters is probably one of the most
remarkable developments of the past decade. Examples of those
commercially available are the NovoGen MMX Bioprinter™, BioBots, the 3D Bioplotter®, Bioassembly Tool, Fab@ Home and Biofactory [188]. The reader is referred to Table 2 for a detailed list of
both non-commercial and commercial extrusion-based bioprinters
used in various tissue and organ construct printing applications.
5. Towards vascularized scale-up tissue fabrication
Although several studies have been performed in EBB, printing
vascularized, metabolically highly active thick tissues such as
333
cardiac, pancreas, lung or liver tissues is still a challenge. In order to
bioprint vascularized thick tissues, robust technologies and protocols should be developed to enable bioprinting of vascular constructs in multiple scales. Since it is very difficult to print capillaries
at the submicron scale using the current technology, one alternative strategy can be bioprinting the macro-vasculature and
expecting the capillaries to be formed by nature. Two alternative
approaches have been considered in the literature: indirect bioprinting by utilizing a fugitive ink that is removed by thermally
induced decrosslinking, leaving a vascular network behind [27,189],
and direct bioprinting of a vasculature network [21,86,190e192].
In the last couple years, several researchers have attempted to
use a fugitive bioink to create vascular channels. These researchers
include Khademhosseini's group [25,61,193] (Fig. 4A1eA2), Dai's
group [194,195] (Fig. 4B1eB2), Lewis and her coworkers [27,132]
(Fig. 4C), and Chen's group [196] In these studies, cell-laden
hydrogels were used as the base material to fabricate the tissue
construct. Integrating the vascular network demonstrated
increased cell viability inside the construct; even regions near
channels exhibited significant differences when compared to regions away from the channels (Fig. 4A2). Although the majority of
them attempted to create a vascular network in macro-scale and
generate an endothelium lining inside the lumen via colonizing
endothelial cells through perfusion, Dai et al. took a step forward
and successfully achieved angiogenesis by sprouting endothelial
cells within a fibrin network loaded with other supporting cells
[197] (Fig. 4B1). Their study demonstrated that creating a vascular
channel with a lumen surface covered with endothelial cells
improved the diffusion of plasma protein and dextran molecule.
Similar angiogenesis has already been developed in lab-on-a-chip
models, where several supporting cells have been attempted and
used in cancer metastasis studies led by Kamm's and George's
groups [198,199]. Despite the great flexibility in bioprinting
Table 2
Extrusion-based bioprinters and their applications.
Bioprinter
Modular tissue printing
Noncommercial platform
bioprinters Custom build 3D printer
Multi-head tissue/organ
building system (MtoBS)
3D-axis bioprinting
system
Multi-nozzle system
Palmetto 3D printer
Multi-material 3D
bioprinting
3-D Scaffold printer
Commercial
bioprinters
Extrusion mechanism
University/company
Pneumatic micro-extrusion
Harvard Medical School and KAIST Skin [32,224], fluidic channels [103], vascular network
[197],
University of Pennsylvania þ MIT Vascular network [196]
The Catholic University of Korea
Liver [51], heart and adipose tissue [64], bone and
cartilage [186], and other heterogeneous tissues [229]
Korea University
Cell-free scaffold [230,231], skin [232]
Pneumatic micro-extrusion
Pneumatic micro-extrusion
Mechanical micro-extrusion
Pneumatic, piezoelectric, and Drexel University
solenoid micro-extrusion
Pneumatic micro-extrusion
Clemson University
Pneumatic micro-extrusion
The Wyss Institute, Harvard
Mechanical micro-extrusion
Fraunhofer Institute for Materials
Research and Beam Technology
University of Iowa
Multi-arm bioprinter [80] Pneumatic and mechanical
micro-extrusion
3D integrated organ
Pneumatic micro-extrusion
printer
BioAssembly tool
Pneumatic and mechanical
micro-extrusion
NovoGen MMX bioprinter Mechanical micro-extrusion
Organovo
3D discovery
Biofactory
3D bioplotter
BioBots
Bioassembly Bot
Fab@ Home
Pneumatic micro-extrusion
Pneumatic micro-extrusion
Pneumatic micro-extrusion
Pneumatic micro-extrusion
Pneumatic micro-extrusion
Mechanical micro-extrusion
RegenHU
RegenHU
EnvisionTec
Biobots
Advanced solutions
Fab@home
BioScaffolder
Pneumatic micro-extrusion
SYS þ ENG
Wake Forest Institute for
Regenerative Medicine
Sciperio/nScrypt
Use
Fibroblasts [16], endothelial cells [233]
3D vascular constructs [172], adipose-derived stem cells
[77]
Vasculature [27]
Acellular scaffolds [143]
Vascularized tissue printing [29], in-situ bone printing
[205]
Keratinocytes [62], muscle [234]
Vascularization and skin [72]
Bone [235], liver [25,236,237], breast cancer [238],
vascularization [25,193]
Cartilage [144]
Air-blood tissue barrier [23]
Bone [136], cell-free scaffold [239]
Vasculature [240]
Human heart [188]
Liver [45], aortic valves [66], filling chondral and
osteochondral defects [73], and ear [241]
Encapsulated proteins [31], heart [34], cartilage [47],
vascularization [137], and bone [242]
334
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
Fig. 4. Bioprinting of vascular and vascularized tissue constructs: (A1) photograph of bioprinted agarose hydrogel filaments representing branched vascular network in a GelMA
hydrogel block and (A2) a high resolution cross-sectional view of GelMA block stained for live and dead cells (reproduced/adapted with permission from Ref. [25]); (B1) sprouting of
endothelium (stained with red fluorescent protein) into capillary network (stained with green fluorescent protein) within fibrin gel on day 9 and (B2) a high resolution image of the
capillary network on day 14 (reproduced/adapted with permission from Ref. [197]); (C) an image acquired during evacuation of the fugitive ink showing channels in GelMA scaffold
(upper-left) which were later glued with 10T½ fibroblasts, HUVECs and human dermal fibroblasts (HUDFs) (reproduced/adapted with permission from Ref. [27]); (D1) a scanning
electron microscopy image of directly bioprinted vascular channels embedded in a large alginate construct (D2) showing L929 mouse fibroblasts in green (reproduced/adapted with
permission from Ref. [190]); (E1) scaffold-free bioprinting of a branched vascular network using 300 mm human skin fibroblast (HSF) spheroids (solid and broken arrows show 1.2
and 0.9 mm in vascular diameter, respectively), where spheroids (E2) fuse and maturate into tissue after 6 days of deposition (reproduced/adapted with permission from Ref. [21]);
(F) fabrication of a perfusable tissue via integration of bioprinted vasculature and fibroblast tissue strands (reproduced/adapted with permission from Ref. [29]), the scare bar
corresponds to 2 mm on the right figure. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
channels and the ability to create angiogenesis, this technology still
faces several challenges. Another way of bioprinting a vascular
network is by using a coaxial nozzle apparatus. A coaxial nozzle
allows direct bioprinting of the vasculature with immediate
crosslinking of hydrogel bioink, generating a smooth and continuous lumen in any desired length [85,190]. The anatomy can be
controlled by controlling the bioprinting parameters, and the shape
of the vascular network can be mediated by bioprinting. The
vasculature can be loaded with cells such as fibroblast and smooth
muscle cells, and can be embedded in a large tissue construct
during bioprinting (Fig. 4D1eD2) [190]. Embedding vascular
channels in hydrogel constructs thus increases viability of cells
compare to viability of cells in bulk hydrogels. In addition to direct
bioprinting of vasculatures, bioprinting of biologically recapitulated
vascular network has been performed using tissue spheroids as
building blocks as shown in Fig. 4E1 [21]. Six days after deposition,
tissue spheroids completely fused and maturated into a vascular
tissue demonstrating the self-assembly ability of tissue spheroids.
In a recent work, this ability was further advanced into a perfusable
hybrid tissue construct, where bioprinting of vasculature was integrated with tissue strands [29], where fibroblast tissue strands
quickly fused to each other, maturated and formed the tissue
around the vasculature (see Fig. 4F).
6. Limitations and challenges
Extrusion-based bioprinting systems is the most convenient
technique for rapidly fabricating 3-D porous cellular structures
[200]. Although this technology lays the foundation for cell
patterning for scale-up tissue and organ fabrication technologies, it
has several limitations, including low resolution, shear-stressinduced cell deformation and limited material selection due to
the need for rapid encapsulation of cells via gelation. Shear stress
on the nozzle tip wall induces a significant drop in the number of
living cells when the cell density or the bioink concentration is
high. Yin et al. demonstrated that the bioprinting process could
induce quantifiable cell death due to changes in dispensing pressure, nozzle geometry and bioink concentration [201]. Therefore,
using optimum process parameters such as such as bioink concentration, nozzle pressure (ideally minimum), nozzle diameter
and loaded cell density, one can overcome these limitations and
challenges to some extent.
Restricted bioink selection and low resolution and accuracy
limits applicability of EBB systems [41]. In addition, sufficiently
high viscosity is essential for the bioink suspension to overcome
surface-tension-driven droplet formation and be drawn in the form
of straight filaments. High viscosity, on the other hand, triggers
clogging inside the nozzle tip and should be optimized considering
the diameter of the nozzle tip. In addition, nozzle clogging is one of
the most common problems faced in EBB, and the bioink solidifies
inside the nozzle tip for several reasons, such as imprecise
adjustment of the temperature on the heating chamber (for thermally crosslinked bioink), splashing/diffusion of the crosslinker
solution into the nozzle (for ionically crosslinked bioink), early
fusion of spheroids before extrusion (for tissue spheroid-based
bioink), coagulation of the bioparticles loaded in the bioink in
relatively small inner nozzle diameter (for micro-carriers),
discontinuity in the pressure overholding the bioink inside the
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
nozzle tip and non-uniform bioink solutions with large fragments
stacking the nozzle opening.
Bioprintable biomaterials constitute a very small percentage of
the biomaterials used in tissue engineering. When designing and
processing new biomaterials, the majority of biomaterials researchers do not consider bioprinting as an end application. Despite
the great progress in last decade, bioprintable biomaterials or
bioinks have several limitations associated with their biological,
immunological, micro-structural, mechanical, rheological and
chemical properties as discussed in details in Section 3.
In addition to the abovementioned limitations, EBB faces
hardware-related challenges. Pneumatically driven EBB systems
require sterilization of the used air from the air dispenser
compressor. Thus, using a filter on the airway would be ideal to
minimize contamination of the printed structures. Sterilization of a
mechanically driven system is more trivial while the mechanical
dispenser head can be easily autoclaved. Mechanically driven systems are affordable, easy to program, portable, and do not need an
air compressor unit and accessories. Pneumatically driven systems
are very precise and accurate; a micro droplet size of 0.5 nL [202]
can be generated using a valve-based system. However, the cost
of the system increases as the precision of the deposition volume
increases. A mechanically driven system necessitates a tighter
tolerance selection on the ram and the nozzle unit. An incorrect
selection during bioprinter head development results in an unnecessary power requirement on the motor, additional friction
forces, leakage of bioink or failure of the nozzle assembly due to
overloading. Mechanically driven systems provide a better printing
ability for semi-solid or solid bioink such as cell aggregates.
Pneumatically driven systems do not generate smooth extrusion of
the semi-solid or solid bioink and require another liquid or gel
medium to deliver the bioink through the nozzle tip. Otherwise, the
bioink can easily attach on the wall of the nozzle. No issues are
foreseeable for gel-based bioprinting due to its liquid nature
because liquids can easily transmit the force equally in all directions
without any entrapment inside the nozzle. One of the most
important aspects of nozzle selection is the friction coefficient on
the wall of the nozzle tip because the friction coefficient mediates
the shear stress, which might be detrimental for cells. Thus, a
surface with a small friction coefficient and one that is easy to
sterilize would be ideal for printing cells, e.g., glass pipettes [203].
Solenoid-based micro-extrusion enables dispensing of a sub-mL
range volume of bioink [204] and is convenient for bioprinting of
low-viscosity bioink materials with an ionic- or UV-irradiationbased crosslinking mechanism. Although high accuracy can be
obtained, a number of factors affect the accuracy and reproducibility of solenoid-based micro-extrusion systems, including the
time lapse between actuation time (where the coil is energized)
and the time when the valve opens; the soft nature of the seal
between the plunger and the valve seat, resulting in compression of
the sealing and time delays; and the need for high actuating
335
pressure to dispense highly viscous bioink. In addition, temperature, and hence viscosity, variations considerably affect the valve
opening time when the bioink has to be displaced for moving the
plunger. Therefore, solenoid-based micro-extrusion systems may
not be convenient for thermally controlled nozzle configurations. In
addition, fabrication of tolerances on the nozzle is important. For
each different dispensing tip mounted, calibration of the valve may
be needed, especially for very long dispensing tips.
7. Future perspective
Extrusion-based bioprinting stands as a promising technique
among bioprinting technologies due to its versatility in printing
various bioink types; its capability in printing porous tissue analogues for enhanced media diffusion and perfusion capabilities;
and its ability to print fully biological, large tissue constructs rapidly
and with acceptable mechanical and biological properties, which
cannot be achieved using other bioprinting techniques, including
laser-based and droplet-based bioprinting. Despite the great
progress and remarkable achievements of the last decade, there is
still much more to be investigated to generate robust and viable
end-products for applications such as pharmaceutics, transplantation and clinics [205]. The trends listed below can be
considered under future perspectives in EBB technology.
7.1. In situ bioprinting
Bioprinting living tissue constructs or cell-laden scaffolds
in vitro has been well studied in the literature. Success has been
achieved with growing tissues in laboratory settings, e.g., thin tissues or tissues that do not need vascularization, including skin
[206] and cartilage [30]. In situ bioprinting, on the other hand, can
enable growth of thick tissues in critical defects with the help of
vascularization driven by nature in the body. Therefore, in situ
bioprinting is a promising direction for bioprinting porous tissue
analogues that can engraft with the endogenous tissue and
generate new tissue along with vascularization through recruitment of endothelial cells into the tissue construct and sprouting of
capillaries from the endogenous tissue.
Very few attempts have been made in in situ bioprinting; only
inkjet-based bioprinting [207,208] and laser-based bioprinting
[209] have been considered in limited capacity. Extrusion-based
bioprinting, on the other hand, has the flexibility and capability
to bioprint tissue analogues with controlled porous architecture. In
order to take the EBB into a robust state in situ, bioprinting ex vivo
on explants (see Fig. 5A) can be considered as a transitional stage,
where explants can be harvested from the animal model, and the
tissue construct can be built and engineered inside the defect.
When the defect model is still alive, it allows cells of native tissue to
migrate and grow through the printed tissue construct or vice
versa. Although bioprinting into an explant model has been
Fig. 5. In situ EBB: (A) bioprinting into a defect ex vivo, (B) bioprinting into defects on animals in vivo, and (C) futuristic bioprinting technologies for plastic surgery in operating
rooms (image courtesy of Christopher Barnatt, ExplainingTheFuture.com).
336
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
performed using inkjet-based bioprinting [210], it has not been
attempted using EBB so far except for a preliminary effort on
printing into a defect on a non-living femur model placed on a
fixture, which was then filled with pre-crosslinked sodium alginate
[73]. The major advantage of printing into ex vivo defect models is
that it provides a translational step towards in situ bioprinting on a
live animal model (see Fig. 5B), which one day will bring the bioprinter technologies from benchside to bedside. In situ bioprinting,
on the other hand, seems to be very promising in developing tissue
analogues directly on the defect model in operating rooms, which
will pave the way to develop associated enabling technologies for
humans in the future (see Fig. 5C). It can be envisioned that in situ
bioprinting into the defect on live models with controlled porosity
can be used for several purposes, such as deep dermal injuries,
composite tissues and flaps, and calvarial or craniofacial defects
during maxillofacial or brain surgeries.
process. In general, culturing cell aggregates for a longer period of
time generates better mechanical properties because cells deposit
more ECM, particularly elastin and collagen proteins; however,
their fusion and adhesion capabilities decrease while maturation is
completed. Thus, cells need to be guided biologically to deposit
satisfactory collagen and elastin in a shorter period of time to
provide mechanical strength; these are the major proteins in the
connective tissue stromal of parenchymal organs. Better mechanical coherency also helps the operator to load the bioink easily
without any challenges; however, aggregation time should be
optimized to facilitate quick fusion capabilities after bioprinting. In
this regard, novel nozzle configurations should be developed that
enable the loading and printing of polymer-free bioink with minimum structural damage, preserving their integrity.
7.2. Investigating new bioink materials
To date, both in vivo and ex vivo gene therapy have been used in
tissue repair [213]; however, bioprinting genes have been studied
to a limited extent [67]. While differentiating stem cells into multiple lineages is crucial in order to recapitulate the tissue biology,
bioprinting genes spatially could potentially overcome this limitation and could allow transduction and differentiation of autologous
cells into multiple lineages per demand spatially. In addition to
bioprinting-mediated ex vivo gene therapy, bioprinting-mediated
in vivo gene therapy can also be used and is very appealing
because it is technically feasible and will be very effective in the
operating room. Bioprinting genes for locally controlled gene
therapy can surpass the limitations of currently available methods,
including direct injection or gene-activated matrices such as potential spreading of genes to non-target sites [214]. Although naked
plasmid DNA (pDNA) can be applied for gene delivery, it typically
results in low transfection efficiency and high toxicity [215],
therefore loading pDNA in biodegradable microparticles has
recently generated promising results for controlled gene delivery.
In this regard, bioprinting will not only allow spatial control over
gene therapy but also enable slow release of the gene vector to the
surrounding cells or tissues. By bioprinting tissue constructs ex vivo
or in vivo, one can engineer the gene therapy through the sustained
and controlled release of genes loaded in microparticles. This way,
new delivery systems can be developed with controlled, localized
and sustained release of genes with high efficiency and low toxicity,
and the release profile can be mediated by altering bioprinting
parameters and releasing multiple genes sequentially and spatiotemporally. This is particularly important for tissue systems with
functionality-graded tissue heterogeneity, such as osteochondral
tissues with multiple osteal and chondral regions interfacing at a
unique zone with extremely unique tissue anatomy. Thus, gene
release systems can efficiently generate such zonal differentiation
gradually.
Although great progress has been made with novel biomaterials
and biomaterial processing techniques, the development of bioinks
that are well suited for EBB and allow one to bioprint mechanically
and biologically enhanced tissue constructs is still a great need.
Particularly, new biomaterials with very quick gelation or solidification capabilities providing a mild environment for cells would be
highly desirable. Despite the great success in developing new
hydrogels for tissue engineering, not all of them have been adopted
to bioprinting. Thus, a new field of study such as “bioprintable
biomaterials” under the biomaterials and biofabrication fields
could be a great leap to promote research in this direction.
One of the major limitations in currently available hydrogelbased bioinks is the lack of environment for promoting differentiation and growth of stem cells into multiple lineages [211]. While
tissues and organs comprise multiple cell types organized spatially,
a bioink that supports organization of the heterocellular nature of
the tissue microstructure should be developed. Although cells in
hydrogels can migrate and proliferate to some extent, the majority
of the currently used hydrogels in bioprinting are biomaterials with
adherent properties for cell attachment [45]. Therefore, hydrogels
that have natural fibers, such as collagen and RGD peptides, can be
reinforced to further improve biological characteristics. One of the
tools for controlling cell behavior could be nanocomposite hydrogels, which can control stem-cell differentiation spatially and
temporally [212]. By combining chemical, mechanical and physical
stimuli, the native tissue structure and physical properties can be
mimicked. The cellular response should amplify and modify the
differentiation status of stem cells [212]. In general, highly novel
hydrogels should be developed to do the following: promote cell
adhesion, proliferation, aggregation and differentiation toward
multiple lineages; exhibit high mechanical integrity and structural
stability without dissolving after bioprinting; facilitate engraftment
with the endogenous tissue without generating immune response;
demonstrate bioprintability with ease of shear thinning, rapid solidification and formability; and be affordable, abundant and
commercially available with appropriate regulatory guidelines for
clinical use.
Polymer-free bioprinting is one of the most exciting directions
in tissue printing. It enables rapid fabrication of tissues and overcomes all the drawbacks associated with polymers, such as
degradation and related toxic products, limited cell infiltration and
encapsulation capability, poor cell migration and proliferation inside the polymer matrix, and a smaller chance of vascularization.
Despite the great advantages, mechanical properties are the major
drawback, and careful investigation should be conducted to achieve
acceptable mechanical rigidity before and after the bioprinting
7.3. EBB-mediated gene therapy
7.4. Bioprinting scale-up tissues and organs
In vitro fabrication of physiologically relevant tissues is a very
sophisticated phenomenon comprising a hierarchical arrangement
of multiple cell types, including a multi-scale network of vasculature in stroma and parenchyma, along with lymphatic vessels and,
occasionally, neural and muscle tissue, depending on the tissue
type. In vitro engineered tissue models that incorporate all of these
components are still far out on the horizon. The major roadblock to
this ambitious goal is multi-scale vascularization [205]. As larger
vasculatures can be bioprinted using EBB systems, controllable
capillary network can be created by nature as already achieved in
hydrogels [198,199]. Since the time-scale of neovascularization and
the post-bioprinting maturation of tissue constructs is not the
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
same, printed parenchymal cells require media and oxygen support
immediately and therefore macrovascular network should be
created with a diffusion distance of 200e300 mm [86] depending on
the biomaterial and its interstitial flow capabilities. In addition,
biomaterials with high micro-porosity should be preferred because
they will overcome the abovementioned issues to some extent.
Bioprinting technology offers a great benefit in the hierarchical
arrangement of cells or building tissue blocks in a 3D microenvironment, but the bioink and the post-bioprinting maturation phase
are as important as the bioprinting process itself. Although
hydrogels such as fibrin and GelMA support neovascularization,
they may not provide the ideal microenvironment and signaling for
survival, motility and differentiation of a wide array of tissuespecific cells, and their stability over prolonged in vitro culture is
weak [216,217]. Thus, tissue-specific cell types can be bioprinted in
a scaffold-free spheroid form (i.e., pancreatic islets or lymphatic
follicles) that is pre-vascularized and can be coated with a very thin
layer of angiogenesis supporting biomaterial (i.e., fibrin). This can
promote formation of contiguous vascular network within the
spheroid along with elongation of sprouts into the scaffold
encapsulating spheroids, which can even facilitate anastomosis of
sprouted vessels between two spheroids. In addition, successful
sprouting of these capillaries from spheroids to the macro-vascular
network is also crucial to make a fully contiguous vascular network.
7.5. Need for high-resolution and fully automated systems
One of the major shortcomings of EBB is the lack of highresolution systems due to the nature of the extrusion process itself. Although certain errors can be induced due to other system
components, such as errors associated with the motion system or
the extrusion process itself has an enormous contribution to the low
resolution. Although very small nozzle tips can be considered
possible, decreasing the nozzle size results in a considerable increase
in the shear stress and corresponding cell damage and death. Thus,
EBB systems should be modified to alleviate this issue. In addition,
lowering the size further increases issues such as nozzle clogging
and the need for elevated dispensing pressure levels. Although a low
electric field can be applied to reduce the size of the printed filaments as widely used in electrohydrodynamic printing [53], cells
should be kept away from the electric field to safely deliver them. A
recent approach in the application of electrohydrodynamic jetting in
inkjet-based bioprinting demonstrates the safe usage of the system
with cells; this approach has the potential to be used in EBB [54]. The
other potential of increasing the resolution is to use a cone-shaped
nozzle (i.e., Taylor cone or regular cone) that has a relatively alleviated shear stress, which reaches its maximum at the end of the
nozzle tip, affecting cells at a minimum duration. In addition to these
approaches, a highly innovative approach might be using a nozzlefree extrusion system that enables the bioink to overcome surfacetension-induced droplet formation.
337
7.6. Bioprinting new types of organs
In addition to bioprinting tissue and organ constructs to replace
their existing counterparts, for a longer-term perspective, the authors also envision bioprinting new types of organs that do not
exist in nature but can be engineered to perform specific and useful
functions, such as treating diseases or enhancing the physiology of
the human body beyond its ordinary capabilities. Such organs can
be either fully biological or in the form of cyborg organs interweaving electronics and biology. A recent work [218] demonstrated
a proof of concept of such a cyborg organ example. Bionic ears were
printed using a hybrid approach via integration of bioprinting
chondrocytes in alginate along with printed silver nanoparticles in
the form of an inductive coil antenna. The cultured cyborg organ
model was then tested and was found to exhibit enhanced auditory
sensing for radio frequency reception (see Fig. 6). Threedimensional printing in that study demonstrated the proof of
concept for cyborg ears, promising a seamless integration of electronics and biology for future off-the-shelf cyborg organs. These
organs can also be constructed fully biologically and even generate
functions that the power system does in daily life, such as producing electricity. With recent advances in understanding the
genomic basis of electric organs (EOs) [219], which exist in electric
eels and produce electricity for communication, sensing, navigation, predation and defense, the possibility of fabricating similar
models of EOs can be considered for future attempts in using such
an organ for transplantation or for replacing batteries for pacemakers [174] or cochlear implants [220] or powering prosthetic
devices.
7.7. Regulatory concerns
Due to its unique capabilities, EBB has been preferred for
fabrication of living tissues and organs, and regulatory issues seem
to be down the way as the technology transforms into products for
clinics and human-use purposes. Currently, there is no regulations
that has been laid down for bioprinting including bioink, bioprinters and bioprinted products such as tissues, and FDA has not
imposed any regulatory restrictions on bioprinting technology yet.
Cutting-edge technologies such as bioprinting cannot be easily
categorized for regulatory purposes while it does not fit into the
general classification of “device”, “drug” or “biologic” under FDA
regulations. Office of Combination Products (OCP) formed by FDA
can handle this situation, where “combination product” is defined
in 21 CFR x3.2(e) as “A product comprised of two or more regulated
components, i.e., drug/device, biologic/device, drug/biologic or
drug/device/biologic, that are physically, chemically, or otherwise
combined or mixed and produced as a single entity” [221]. The OCP
does not conduct product reviews but assigns combination products to the appropriate FDA center (i.e., the Center for Drug Evaluation and Research (CDER), The Center for Biologics Evaluation
Fig. 6. 3D printed cyborg ears: (A) bioprinting of anatomically correct cartilage scaffold loaded with chondrocytes along with printing of coil antenna; (B) scaffolds were cultured 10
weeks, resulting in neocartilaginous tissue in alginate matrix, (C) 3D printed complementary ears (right and left) demonstrated the ability to listen to stereophonic audio music
(reproduced/adapted with permission from Ref. [218]).
338
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
and Research (CBER) and the Center for Devices and Radiological
Health (CDRH)), ensures timely and effective premarket review and
appropriate post market regulations, and serves as a resource to
industry and the FDA center's review staff [221]. Ultimately, both
the bioprinted tissues and the 3D bioprinter itself could be classified as combination products. The bioprinter is classifiable as a
medical device as it is used for treating humans and is intended to
affect the structure and function of the human body. The bioink can
be classified as a biologic (cells) or a drug (genes, growth factors.
etc.). The tissues printed by the bioprinter could be classified as a
biologic. Currently, there are only few companies in the world
[188]; however, with the increasing global interest and needs, more
businesses will be established in the growing bioprinting market
and success of the first technology going through FDA regulations
will be exemplary for preceding technologies and products.
In addition to regulatory concerns with bioprinting, ethical
concerns will be another fact to be considered for future attempts.
Although, majority of the trial have been made on animals, ethical
concerns will raise when printing tissues or organs for transplant to
humans. Patients' own stems will be required to overcome rejection issues and patient may not be willing to allow their cells went
through several procedures in order to 3D bioprint an organ such as
mixing their cells with biomaterials obtained from animals. In
addition to those, new types of organs can also be manipulated and
organs for superior functionalities, which can mutant the human
body or give some additional superiority to it such as energy
generating organs or muscles that do not produce lactic acid and
eliminates tireless nature of the body and give some extra
competitiveness to the athletes during the competitions. This is not
ethical and may not be likely to be accepted in the future. The
religion and cultural norms may also play an important role in
ethical concerns such as transplantation of patient own cells within
a scaffold made from animal proteins will not be acceptable for
some religious and cultural rules.
8. Conclusion
This review for the first time presents the recent advances in
EBB systems and their components, including the technology, the
bioink, process configurations, bioprinters and enabling technologies for vascularized tissue fabrication. Despite the great benefits
and flexibility of printing a wide range of bioinks and advantages
such as the ability to bioprint mechanically sound, structurally integrated, scale-up tissue constructs, the technology currently faces
several limitations, particularly in the resolution of printed features, the ability to define anatomically correct shapes and the
ability to generate scale-up tissue constructs. In addition to a discussion of recent progress in the field, the paper provides the
reader with the limitations of the technology and outlines promising directions for new future prospects that will enable viable
solutions for applications ranging from tissue engineering and
pharmaceutics to clinical uses.
Acknowledgment
This work has been supported by National Science Foundation
CMMI Awards 1349716 and 1462232, Diabetes in Action Research
and Education Foundation grant # 426 and the Grow Iowa Values
Funds through The University of Iowa. We would like to thank Ms.
Laura L. Hupp, associate attorney in Shook, Hardy & Bacon L.L.P., for
her insight on regulatory issues. We thank Melanie Laverman,
Rebecca Barrett and Dr. Adil Akkouch from The University of Iowa
for for their assistance with typesetting the article. The authors
would like to express their gratitude to Dr. Christopher Barnatt
(ExplainingTheFuture.com), Prof. J. Alblas (University Medical
Center Utrecht), Prof. A. Khademhosseini (Harvard University), Prof.
J. Hosek (Czech Technical University in Prague), Prof. W. Sun (Drexel
University and Tsinghua University), Prof. J.A. Lewis (Harvard University), Prof. G.D. Prestwich (University of Utah), and Prof. M. Mc
Alpine (Princeton University) in providing the high-quality images
of some figures.
The authors confirm that there are no known conflicts of interest
associated with this publication and there has been no significant
financial support for this work that could have influenced its outcome.
References
[1] C. Abeykoon, P.J. Martin, A.L. Kelly, E.C. Brown, A review and evaluation of
melt temperature sensors for polymer extrusion, Sensors Actuators A Phys.
182 (2012) 16e27, http://dx.doi.org/10.1016/j.sna.2012.04.026.
[2] H. Lipson, M. Kurman, Fabricated: the New World of 3D Printing, Wiley,
2013.
[3] I. Zein, D.W. Hutmacher, K.C. Tan, S.H. Teoh, Fused deposition modeling of
novel scaffold architectures for tissue engineering applications, Biomaterials
23 (2002) 1169e1185, http://dx.doi.org/10.1016/S0142-9612(01)00232-0.
[4] T.H. Ang, F.S.A. Sultana, D.W. Hutmacher, Y.S. Wong, J.Y.H. Fuh, X.M. Mo, et
al., Fabrication of 3D chitosanehydroxyapatite scaffolds using a robotic
dispensing system, Mater. Sci. Eng. C 20 (2002) 35e42 doi: http://dx.doi.org/
10.1016/S0928-4931(02)00010-3.
[5] D.W. Hutmacher, M. Sittinger, M. Risbud, Scaffold-based tissue engineering:
rationale for computer-aided design and solid free-form fabrication systems,
Trends Biotechnol. 22 (2004) 354e362 doi: http://dx.doi.org/10.1016/j.
tibtech.2004.05.005.
[6] B. Rai, S.H. Teoh, D.W. Hutmacher, T. Cao, K.H. Ho, Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2, Biomaterials 26 (2005)
3739e3748 doi: http://dx.doi.org/10.1016/j.biomaterials.2004.09.052.
[7] S.J. Hollister, R.A. Levy, T.-M. Chu, J.W. Halloran, S.E. Feinberg, An imagebased approach for designing and manufacturing craniofacial scaffolds, Int.
J. Oral Maxillofac. Surg. 29 (2000) 66 doi: http://dx.doi.org/10.1016/S09015027(00)80128-9.
[8] C.Y. Lin, N. Kikuchi, S.J. Hollister, A novel method for biomaterial scaffold
internal architecture design to match bone elastic properties with desired
porosity, J. Biomech. 37 (2004) 623e636, http://dx.doi.org/10.1016/
j.jbiomech.2003.09.029.
[9] R.M. Schek, E.N. Wilke, S.J. Hollister, P.H. Krebsbach, Combined use of
designed scaffolds and adenoviral gene therapy for skeletal tissue engineering, Biomaterials 27 (2006) 1160e1166 doi: http://dx.doi.org/10.1016/j.
biomaterials.2005.07.029.
[10] D.J. Odde, M.J. Renn, Laser-guided direct writing of living cells, Biotechnol.
Bioeng. 67 (2000) 312.
[11] L. Pardo, W.C. Wilson, T. Boland, Characterization of patterned selfassembled monolayers and protein arrays generated by the ink-jet
method, Langimur (2003) 1462e1466.
[12] V. Mironov, T. Boland, T. Trusk, G. Forgacs, R.R. Markwald, Organ printing:
computer-aided jet-based 3D tissue engineering, Trends Biotechnol. 21
(2003) 157e161 doi: http://dx.doi.org/10.1016/S0167-7799(03)00033-7.
[13] F. Guillemot, V. Mironov, M. Nakamura, Bioprinting is coming of age: report
from the International Conference on Bioprinting and Biofabrication in
Bordeaux (3B'09), Biofabrication 2 (2010) 010201, http://dx.doi.org/10.1088/
1758-5082/2/1/010201.
[14] A. Pfister, R. Landers, A. Laib, U. Hübner, R. Schmelzeisen, R. Mülhaupt,
Biofunctional rapid prototyping for tissue-engineering applications: 3D
bioplotting versus 3D printing, J. Polym. Sci. Part A Polym. Chem. 42 (2004)
624e638, http://dx.doi.org/10.1002/pola.10807.
[15] S.W. Khalil Saif, Biopolymer deposition for freeform fabrication of hydrogel
tissue constructs, Mater. Sci. Eng. C 27 (2007) 469e478, http://dx.doi.org/
10.1016/j.msec.2006.05.023.
[16] S. Khalil, J. Nam, W. Sun, Multi-nozzle deposition for construction of 3-D
biopolymer tissue scaffolds, Rapid Prototyp. J. 11 (2005) 9e17, http://
dx.doi.org/10.1108/13552540510573347.
[17] I. Elloumi-Hannachi, M. Yamato, T. Okano, Cell sheet engineering: a unique
nanotechnology for scaffold-free tissue reconstruction with clinical applications in regenerative medicine, J. Intern. Med. 267 (2010) 54e70, http://
dx.doi.org/10.1111/j.1365-2796.2009.02185.x.
[18] T. Boland, V. Mironov, A. Gutowska, E.A. Roth, R.R. Markwald, Cell and organ
printing 2: fusion of cell aggregates in three-dimensional gels, Anat. Rec. Part
A Discov. Mol. Cell. Evol. Biol. 272A (2003) 497e502, http://dx.doi.org/
10.1002/ar.a.10059.
[19] K. Jakab, A. Neagu, V. Mironov, R.R. Markwald, G. Forgacs, Engineering biological structures of prescribed shape using self-assembling multicellular
systems, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2864e2869, http://
dx.doi.org/10.1073/pnas.0400164101.
[20] V. Mironov, R.P. Visconti, V. Kasyanov, G. Forgacs, C.J. Drake, R.R. Markwald,
Organ printing: tissue spheroids as building blocks, Biomaterials 30 (2009)
2164e2174, http://dx.doi.org/10.1016/j.biomaterials.2008.12.084.
[21] C. Norotte, F. Marga, L. Niklason, G. Forgacs, Scaffold-free vascular tissue
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
engineering using bioprinting, Biomaterials 30 (2010) 5910e5917, http://
dx.doi.org/10.1016/j.biomaterials.2009.06.034.
S.V. Murphy, A. Atala, 3D bioprinting of tissues and organs, Nat. Biotech. 32
(2014) 773e785, http://dx.doi.org/10.1038/nbt.2958.
L. Horv
ath, Y. Umehara, C. Jud, F. Blank, A. Petri-Fink, B. Rothen-Rutishauser,
Engineering an in vitro air-blood barrier by 3D bioprinting, Sci. Rep. 5 (2015)
7974, http://dx.doi.org/10.1038/srep07974.
C. Almeida, T. Serra, M. Oliveira, J. Planell, M. Barbosa, M. Navarro, Impact of
3-D printed PLA- and chitosan-based scaffolds on human monocyte/
macrophage responses: unraveling the effect of 3-D structures on inflammation, Acta Biomater. 10 (2014) 613e622, http://dx.doi.org/10.1016/
j.actbio.2013.10.035.
L.E. Bertassoni, J.C. Cardoso, V. Manoharan, A.L. Cristino, N.S. Bhise,
W. Araujo, et al., Direct-write bioprinting of cell-laden methacrylated gelatin
hydrogels, Biofabrication 6 (2014) 024105, http://dx.doi.org/10.1088/17585082/6/2/024105.
S.M. Ehsan, K.M. Welch-Reardon, M.L. Waterman, C.C.W. Hughes,
S.C. George, A three-dimensional in vitro model of tumor cell intravasation,
Integr. Biol. (Camb.) 6 (2014) 603e610, http://dx.doi.org/10.1039/
c3ib40170g.
D. Kolesky, R. Truby, A.S. Gladman, T. Busbee, K. Homan, J. Lewis, Bioprinting:
3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs,
Adv. Mater. 26 (2014) 2966, http://dx.doi.org/10.1002/adma.201470124.
F. Marga, K. Jakab, C. Khatiwala, B. Shepherd, S. Dorfman, B. Hubbard, et al.,
Toward engineering functional organ modules by additive manufacturing,
Biofabrication. 4 (2012) 22001. http://stacks.iop.org/1758-5090/4/i¼2/
a¼022001.
Y. Yu, Y. Zhang, I.T. Ozbolat, A hybrid bioprinting approach for scale-up tissue
fabrication, J. Manuf. Sci. Eng. 136 (2014) 061013, http://dx.doi.org/10.1115/
1.4028511.
W. Zhang, Q. Lian, D. Li, K. Wang, D. Hao, W. Bian, et al., Cartilage repair and
subchondral bone migration using 3D printing osteochondral composites: a
one-year-period study in rabbit trochlea, Biomed. Res. Int. 2014 (2014)
746138, http://dx.doi.org/10.1155/2014/746138.
M.T. Poldervaart, H. Wang, J. van der Stok, H. Weinans, S.C.G. Leeuwenburgh,
€
F.C. Oner,
et al., Sustained release of BMP-2 in bioprinted alginate for
osteogenicity in mice and rats, PLoS One 8 (2013) e72610, http://dx.doi.org/
10.1371/journal.pone.0072610.
W. Lee, J.C. Debasitis, V.K. Lee, J.H. Lee, K. Fischer, K. Edminster, et al., Multilayered culture of human skin fibroblasts and keratinocytes through threedimensional freeform fabrication, Biomaterials 30 (2009) 1587e1595,
http://dx.doi.org/10.1016/j.biomaterials.2008.12.009.
P. Godoy, N.J. Hewitt, U. Albrecht, M.E. Andersen, N. Ansari, S. Bhattacharya,
et al., Recent Advances in 2D and 3D In Vitro Systems Using Primary Hepatocytes, Alternative Hepatocyte Sources and Non-parenchymal Liver Cells
and Their Use in Investigating Mechanisms of Hepatotoxicity, Cell Signaling
and ADME, 2013, http://dx.doi.org/10.1007/s00204-013-1078-5.
R. Gaetani, P. Doevendans, C.H.G. Metz, J. Alblas, E. Messina, A. Giacomello, et
al., Cardiac tissue engineering using tissue printing technology and human
cardiac progenitor cells, Biomaterials 33 (2012) 1782e1790, http://
dx.doi.org/10.1016/j.biomaterials.2011.11.003.
C.L. Ventola, Medical applications for 3D printing: current and projected
uses, P&T 39 (2014) 704e711.
T.Q. Huang, X. Qu, J. Liu, S. Chen, 3D printing of biomimetic microstructures
for cancer cell migration, Biomed. Microdevices 16 (2014) 127e132, http://
dx.doi.org/10.1007/s10544-013-9812-6.
K. Jakab, C. Norotte, F. Marga, K. Murphy, G. Vunjak, G. Forgacs, Tissue engineering by self-assembly and bio-printing of living cells, Biofabrication. 2
(2010) 22001. http://stacks.iop.org/1758-5090/2/i¼2/a¼022001.
L. Moroni, J.R. De Wijn, C.A. Van Blitterswijk, 3D fiber-deposited scaffolds for
tissue engineering: influence of pores geometry and architecture on dynamic
mechanical properties, Biomaterials 27 (2006) 974e985, http://dx.doi.org/
10.1016/j.biomaterials.2005.07.023.
J.E. Snyder, Q. Hamid, C. Wang, R. Chang, K. Emami, H. Wu, et al., Bioprinting
cell-laden matrigel for radioprotection study of liver by pro-drug conversion
in a dual-tissue microfluidic chip, Biofabrication 3 (2011) 034112, http://
dx.doi.org/10.1088/1758-5082/3/3/034112.
J.D. Perkins, Are we reporting the same thing?: comments, Liver Transpl. 13
(2007) 465e466, http://dx.doi.org/10.1002/lt.
A.B. Dababneh, I.T. Ozbolat, Bioprinting technology: a current state-of-theart review, J. Manuf. Sci. Eng. 136 (2014) 061016, http://dx.doi.org/
10.1115/1.4028512.
F.P.W. Melchels, M.N. Domingos, T.J. Klein, J. Malda, P.J. Bartolo,
D.W. Hutmacher, Additive manufacturing of tissues and organs, Prog. Polym.
http://dx.doi.org/10.1016/
Sci.
37
(2012)
1079e1104,
j.progpolymsci.2011.11.007.
A. Khoda, I.T. Ozbolat, B. Koc, Engineered tissue scaffolds with variational
porous architecture, J. Biomech. Eng. 133 (2011) 011001, http://dx.doi.org/
10.1115/1.4002933.
S.M. Giannitelli, D. Accoto, M. Trombetta, A. Rainer, Current trends in the
design of scaffolds for computer-aided tissue engineering, Acta Biomater. 10
(2014) 580e594 doi: http://dx.doi.org/10.1016/j.actbio.2013.10.024.
A. Skardal, J. Zhang, L. McCoard, X. Xu, S. Oottamasathien, G.D. Prestwich,
Photocrosslinkable hyaluronan-gelatin hydrogels for two-step bioprinting,
Tissue Eng. Part A 16 (2010) 2675e2685, http://dx.doi.org/10.1089/
339
ten.TEA.2009.0798.
[46] G. Fielding, A. Bandyopadhyay, S. Bose, Effects of silica and zinc oxide doping
on mechanical and biological properties of 3D printed tricalcium phosphate
tissue engineering scaffolds, Dent. Mater. 28 (2012) 113e122, http://
dx.doi.org/10.1016/j.dental.2011.09.010.
[47] J. Visser, B. Peters, T.J. Burger, J. Boomstra, W.J. Dhert, F.P.W. Melchels, et al.,
Biofabrication of multi-material anatomically shaped tissue constructs, Biofabrication 5 (2013) 035007, http://dx.doi.org/10.1088/1758-5082/5/3/
035007.
[48] T. Billiet, E. Gevaert, T. De Schryver, M. Cornelissen, P. Dubruel, The 3D
printing of gelatin methacrylamide cell-laden tissue-engineered constructs
with high cell viability, Biomaterials 35 (2014) 49e62, http://dx.doi.org/
10.1016/j.biomaterials.2013.09.078.
[49] N.G. Durmus, S. Tasoglu, U. Demirci, Bioprinting: functional droplet networks, Nat. Mater. 12 (2013) 478e479, http://dx.doi.org/10.1038/nmat3665.
[50] F.P.W. Melchels, W.J. Dhert, D.W. Hutmacher, J. Malda, Development and
characterisation of a new bioink for additive tissue manufacturing, J. Mater.
Chem. B 2 (2014) 2282, http://dx.doi.org/10.1039/c3tb21280g.
[51] F. Pati, D. Ha, J. Jang, H.H. Han, J. Rhie, D.-W. Cho, Biomimetic 3D tissue
printing for soft tissue regeneration, Biomaterials 62 (2015) 164e175, http://
dx.doi.org/10.1016/j.biomaterials.2015.05.043.
[52] T. Xu, W. Zhao, J.-M. Zhu, M.Z. Albanna, J.J. Yoo, A. Atala, Complex heterogeneous tissue constructs containing multiple cell types prepared by inkjet
printing technology, Biomaterials 34 (2013) 130e139 doi: http://dx.doi.org/
10.1016/j.biomaterials.2012.09.035.
[53] L. Gasperini, D. Maniglio, A. Motta, C. Migliaresi, An electrohydrodynamic
bioprinter for alginate hydrogels containing living cells, Tissue Eng. Part C.
Methods 21 (2015) 123e132, http://dx.doi.org/10.1089/ten.TEC.2014.0149.
[54] P.A. Eagles, A.N. Qureshi, S.N. Jayasinghe, Electrohydrodynamic jetting of
mouse neuronal cells, Biochem. J. 394 (2006) 375e378, http://dx.doi.org/
10.1042/BJ20051838.
[55] U. Demirci, G. Montesano, Single cell epitaxy by acoustic picolitre droplets,
Lab Chip 7 (2007) 1139e1145, http://dx.doi.org/10.1039/b704965j.
[56] H. Lin, D. Zhang, P.G. Alexander, G. Yang, J. Tan, A.W.-M. Cheng, et al.,
Application of visible light-based projection stereolithography for live cellscaffold fabrication with designed architecture, Biomaterials 34 (2013)
331e339, http://dx.doi.org/10.1016/j.biomaterials.2012.09.048.
zel, A. Souquet, L. Hallo, F. Guillemot, Bioprinting by laser-induced
[57] C. Me
forward transfer for tissue engineering applications: jet formation
modeling, Biofabrication 2 (2010) 014103, http://dx.doi.org/10.1088/17585082/2/1/014103.
[58] A.N. Mehesz, J. Brown, Z. Hajdu, W. Beaver, J.V.L. da Silva, R.P. Visconti, et al.,
Scalable robotic biofabrication of tissue spheroids, Biofabrication. 3 (2011)
25002. http://stacks.iop.org/1758-5090/3/i¼2/a¼025002.
[59] J.H.Y. Chung, S. Naficy, Z. Yue, R. Kapsa, A. Quigley, S.E. Moulton, et al., Bio-ink
properties and printability for extrusion printing living cells, Biomater. Sci. 1
(2013) 763, http://dx.doi.org/10.1039/c3bm00012e.
[60] S. Khalil, W. Sun, Bioprinting endothelial cells with alginate for 3D tissue
constructs, J. Biomech. Eng. 131 (2009) 111002, http://dx.doi.org/10.1115/
1.3128729.
[61] J. Malda, J. Visser, F.P. Melchels, T. Jüngst, W.E. Hennink, W.J.A. Dhert, et al.,
25th anniversary article: engineering hydrogels for biofabrication, Adv.
Mater. 25 (2013) 5011e5028, http://dx.doi.org/10.1002/adma.201302042.
[62] S.V. Murphy, A. Skardal, A. Atala, Evaluation of hydrogels for bio-printing
applications, J. Biomed. Mater. Res. Part A 101A (2013) 272e284, http://
dx.doi.org/10.1002/jbm.a.34326.
[63] R. Levato, J. Visser, J. Planell, E. Engel, J. Malda, M. Mateos-Timoneda, Biofabrication of tissue constructs by 3D bioprinting of cell-laden microcarriers,
Biofabrication 6 (2014) 35020. http://stacks.iop.org/1758-5090/6/i¼3/
a¼035020.
[64] F. Pati, J. Jang, D.-H. Ha, S. Won Kim, J.-W. Rhie, J.-H. Shim, et al., Printing
three-dimensional tissue analogues with decellularized extracellular matrix
bioink, Nat. Commun. 5 (2014) 3935, http://dx.doi.org/10.1038/
ncomms4935.
[65] M. Gou, X. Qu, W. Zhu, M. Xiang, J. Yang, K. Zhang, et al., Bio-inspired
detoxification using 3D-printed hydrogel nanocomposites, Nat. Commun. 5
(2014) 3774, http://dx.doi.org/10.1038/ncomms4774.
[66] B. Duan, L. Hockaday, K.H. Kang, J.T. Butcher, 3D bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels, J. Biomed. Mater.
Res. Part A 101 A (2013) 1255e1264, http://dx.doi.org/10.1002/jbm.a.34420.
[67] R. Chang, J. Nam, W. Sun, Effects of dispensing pressure and nozzle diameter
on cell survival from solid freeform fabrication-based direct cell writing,
Tissue Eng. Part A 14 (2008) 41e48, http://dx.doi.org/10.1089/
ten.a.2007.0004.
[68] C.M. Owens, F. Marga, G. Forgacs, C.M. Heesch, Biofabrication and testing of a
fully cellular nerve graft, Biofabrication. 5 (2013) 45007. http://dx.doi.org/10.
1088/1758-5082/5/4/045007.
[69] Yin Yu, I.T. Ozbolat, Tissue strands as “bioink” for scale-up organ printing,
Conf. Proc. Annu. Int. Conf. IEEE 2014 (2014) 1428e1431, http://dx.doi.org/
10.1109/EMBC.2014.6943868.
€kel, M. Vogt, et al.,
[70] D.F. Duarte Campos, A. Blaeser, A. Korsten, S. Neuss, J. Ja
The stiffness and structure of three-dimensional printed hydrogels direct the
differentiation of mesenchymal stromal cells toward adipogenic and osteogenic lineages, Tissue Eng. Part A 00 (2014) 1e17, http://dx.doi.org/10.1089/
ten.TEA.2014.0231.
340
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
[71] A. Gregor, J. Hosek, 3D printing methods of biological scaffolds used in tissue
engineering, Rom. Rev. Precis. Mech. Opt. Mechatron. 3 (2011) 143e148.
[72] C.M. Smith, A. Stone, R.L. Stewart, M.W. Simpkins, A.M. Kachurin, D. Ph, et al.,
Three-dimensional bioassembly tool for generating viable tissue-engineered
constructs, Tissue Eng. 10 (2004) 1566e1576, http://dx.doi.org/10.1089/
ten.2004.10.1566.
[73] D.L. Cohen, J.I. Lipton, L.J. Bonassar, H. Lipson, Additive manufacturing for in
situ repair of osteochondral defects, Biofabrication 2 (2010) 035004, http://
dx.doi.org/10.1088/1758-5082/2/3/035004.
[74] J.L. Drury, D.J. Mooney, Hydrogels for tissue engineering: Scaffold design
variables and applications, Biomaterials 24 (2003) 4337e4351, http://
dx.doi.org/10.1016/S0142-9612(03)00340-5.
[75] E.M. Ahmed, Hydrogel: preparation, characterization, and applications,
J. Adv. Res. 6 (2013) 105e121, http://dx.doi.org/10.1016/j.jare.2013.07.006.
[76] J. Cohen, K.L. Zaleski, G. Nourissat, T.P. Julien, M. Randolph, M.J. Yaremchuk,
Survival of porcine mesenchymal stem cells over the alginate recovered
cellular method, J. Biomed. Mater. Res. A 96 (2011) 93e99, http://dx.doi.org/
10.1002/jbm.a.32961.
[77] J. Jia, D.J. Richards, S. Pollard, Y. Tan, J. Rodriguez, R.P. Visconti, et al., Engineering alginate as bioink for bioprinting, Acta Biomater. 10 (2014)
4323e4331, http://dx.doi.org/10.1016/j.actbio.2014.06.034.
[78] S. Wüst, R. Müller, S. Hofmann, 3D bioprinting of complex channels e effects
of material, orientation, geometry and cell embedding, J. Biomed. Mater. Res.
A (2014), http://dx.doi.org/10.1002/jbm.a.35393.
[79] S. Ahn, H. Lee, L.J. Bonassar, G. Kim, Cells (MC3T3-E1)-laden alginate scaffolds
fabricated by a modified solid-freeform fabrication process supplemented
with an aerosol spraying, Biomacromolecules 13 (2012) 2997e3003, http://
dx.doi.org/10.1021/bm3011352.
[80] I.T. Ozbolat, H. Chen, Y. Yu, Development of “Multi-arm Bioprinter” for
hybrid biofabrication of tissue engineering constructs, Robot. Comput. Integr.
Manuf. 30 (2014) 295e304, http://dx.doi.org/10.1016/j.rcim.2013.10.005.
[81] S. Ahn, H. Lee, J. Puetzer, L.J. Bonassar, G. Kim, Fabrication of cell-laden threedimensional alginate-scaffolds with an aerosol cross-linking process,
J. Mater. Chem. 22 (2012) 18735, http://dx.doi.org/10.1039/c2jm33749e.
[82] L. Geng, W. Feng, D.W. Hutmacher, Y.S. Wong, H.T. Loh, J.Y.H. Fuh, Direct
writing of chitosan scaffolds using a robotic system, Rapid Prototyp. J. 11
(2005) 90e97, http://dx.doi.org/10.1108/13552540510589458.
[83] L. Zhang, J. Huang, T. Si, R.X. Xu, Coaxial electrospray of microparticles and
nanoparticles for biomedical applications, Changes 29 (2012) 997e1003,
http://dx.doi.org/10.1586/erd.12.58.
[84] P. Davoodi, F. Feng, Q. Xu, W.-C. Yan, Y.W. Tong, M.P. Srinivasan, et al., Coaxial electrohydrodynamic atomization: microparticles for drug delivery
applications, J. Control. Release (2014), http://dx.doi.org/10.1016/
j.jconrel.2014.12.004.
[85] Y. Zhang, Y. Yu, A. Akkouch, A. Dababneh, F. Dolati, I.T. Ozbolat, In vitro study
of directly bioprinted perfusable vasculature conduits, Biomater. Sci. 3
(2015) 134e143, http://dx.doi.org/10.1039/C4BM00234B.
[86] Y. Zhang, Y. Yu, I.T. Ozbolat, Direct bioprinting of vessel-like tubular microfluidic channels, J. Nanotechnol. Eng. Med. 4 (2013) 21001, http://dx.doi.org/
10.1115/1.4024398.
[87] M. Ma, A. Chiu, G. Sahay, J.C. Doloff, N. Dholakia, J. Cohen, et al., Core-shell
hydrogel microcapsules for improved islets encapsulation 2 (2014) 1e12,
http://dx.doi.org/10.1002/adhm.201200341.
[88] J.A. Rowley, G. Madlambayan, D.J. Mooney, Alginate hydrogels as synthetic
extracellular matrix materials, Biomaterials 20 (1999) 45e53 doi: http://dx.
doi.org/10.1016/S0142-9612(98)00107-0.
[89] M.A. Lawson, J.E. Barralet, I. Wang, R.M. Shelton, J.T. Triffitt, Adhesion and
growth of bone marrow stromal cells on modified alginate hydrogels, Tissue
Eng. 10 (2004) 1480e1491, http://dx.doi.org/10.1089/ten.2004.10.1480.
[90] S.Y. Ong, J. Wu, S.M. Moochhala, M.H. Tan, J. Lu, Development of a chitosanbased wound dressing with improved hemostatic and antimicrobial properties, Biomaterials 29 (2008) 4323e4332, http://dx.doi.org/10.1016/
j.biomaterials.2008.07.034.
[91] Y. Zhang, J.R. Venugopal, A. El-Turki, S. Ramakrishna, B. Su, C.T. Lim, Electrospun biomimetic nanocomposite nanofibers of hydroxyapatite/chitosan
for bone tissue engineering, Biomaterials 29 (2008) 4314e4322, http://
dx.doi.org/10.1016/j.biomaterials.2008.07.038.
[92] L. Ma, C. Gao, Z. Mao, J. Zhou, J. Shen, X. Hu, et al., Collagen/chitosan porous
scaffolds with improved biostability for skin tissue engineering, Biomaterials
24 (2003) 4833e4841, http://dx.doi.org/10.1016/S0142-9612(03)00374-0.
[93] Y. Hong, H. Song, Y. Gong, Z. Mao, C. Gao, J. Shen, Covalently crosslinked
chitosan hydrogel: properties of in vitro degradation and chondrocyte
encapsulation, Acta Biomater. 3 (2007) 23e31, http://dx.doi.org/10.1016/
j.actbio.2006.06.007.
[94] T. Hao, N. Wen, J.K. Cao, H.B. Wang, S.H. Lü, T. Liu, et al., The support of matrix
accumulation and the promotion of sheep articular cartilage defects repair
in vivo by chitosan hydrogels, Osteoarthr. Cartil. 18 (2010) 257e265, http://
dx.doi.org/10.1016/j.joca.2009.08.007.
[95] X. Ren, Y. Kim, J. Zhou, Design and fabrication of chitosan for application of
artificial photosynthesis 3 (2013) 739e746.
[96] M. Rinaudo, Chitin and chitosan: properties and applications, Prog. Polym.
http://dx.doi.org/10.1016/
Sci.
31
(2006)
603e632,
j.progpolymsci.2006.06.001.
[97] K. Ye, R. Felimban, K. Traianedes, S.E. Moulton, G.G. Wallace, J. Chung, et al.,
Chondrogenesis of infrapatellar fat pad derived adipose stem cells in 3D
[98]
[99]
[100]
[101]
[102]
[103]
[104]
[105]
[106]
[107]
[108]
[109]
[110]
[111]
[112]
[113]
[114]
[115]
[116]
[117]
[118]
[119]
[120]
printed chitosan scaffold, PLoS One 9 (2014), http://dx.doi.org/10.1371/
journal.pone.0099410.
mez-Guille
n, B. Gime
nez, M.E. Lo
pez-Caballero, M.P. Montero,
M.C. Go
Functional and bioactive properties of collagen and gelatin from alternative
sources: a review, Food Hydrocoll. 25 (2011) 1813e1827, http://dx.doi.org/
10.1016/j.foodhyd.2011.02.007.
J. Kuijpers, P.B. Van Wachem, M.J. Van Luyn, J. Plantinga, G.H.M. Engbers,
J. Krijgsveld, et al., In vivo compatibility and degradation of crosslinked
gelatin gels incorporated in knitted Dacron, J. Biomed. Mater. Res. 51 (2000)
136e145,
http://dx.doi.org/10.1002/(SICI)1097-4636(200007)51:1<136::
AID-JBM18>3.0.CO;2-W.
Q. Xing, K. Yates, C. Vogt, Z. Qian, M.C. Frost, F. Zhao, Increasing mechanical
strength of gelatin hydrogels by divalent metal ion removal, Sci. Rep. 4
(2014) 4706, http://dx.doi.org/10.1038/srep04706.
X. Wang, Y. Yan, Y. Pan, Z. Xiong, Generation of three-dimensional hepatocyte/gelatin structures with rapid prototyping system, Tissue Eng. 12 (2006)
83e90, http://dx.doi.org/10.1089/ten.2006.12.ft-16.
I. Van Den Bulcke, B. Bogdanov, N. De Rooze, E.H. Schacht, M. Cornelissen,
H. Berghmans, Structural and rheological properties of methacrylamide
modified gelatin hydrogels, Biomacromolecules 1 (2000) 31e38, http://
dx.doi.org/10.1021/bm990017d.
W. Lee, V. Lee, S. Polio, P. Keegan, J.H. Lee, K. Fischer, et al., On-demand threedimensional freeform fabrication of multi-layered hydrogel scaffold with
fluidic channels, Biotechnol. Bioeng. 105 (2010) 1178e1186, http://
dx.doi.org/10.1002/bit.22613.
H. Oxlund, T.T. Andreassen, The roles of hyaluronic acid, collagen and elastin
in the mechanical properties of connective tissues, J. Anat. 131 (1980)
611e620.
A. Migliore, M. Granata, Intra-articular use of hyaluronic acid in the treatment of osteoarthritis, Clin. Interv. Aging 3 (2008) 365e369.
J.Y. Park, J.-C. Choi, J.-H. Shim, J.-S. Lee, H. Park, S.W. Kim, et al.,
A comparative study on collagen type I and hyaluronic acid dependent cell
behavior for osteochondral tissue bioprinting, Biofabrication 6 (2014)
035004, http://dx.doi.org/10.1088/1758-5082/6/3/035004.
O. Jeon, S.J. Song, K.-J. Lee, M.H. Park, S.-H. Lee, S.K. Hahn, et al., Mechanical
properties and degradation behaviors of hyaluronic acid hydrogels crosslinked at various cross-linking densities, Carbohydr. Polym. 70 (2007)
251e257, http://dx.doi.org/10.1016/j.carbpol.2007.04.002.
S. Gerecht, J. Burdick, L.S. Ferreira, S. Townsend, R. Langer, G. VunjakNovakovic, Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells, Proc. Natl. Acad. Sci. U. S. A. 104
(2007) 11298e11303, http://dx.doi.org/10.1073/pnas.0703723104.
N. Dana, V. Parker, M. Meredith, G. Mark, S. Lori, Photocrosslinkable Hyaluronan as a Scaffold for Articular Cartilage Repair, vol. 32, 2004, pp.
391e397.
A. Skardal, A. Atala, Biomaterials for integration with 3-D bioprinting, Ann.
Biomed. Eng. (2014), http://dx.doi.org/10.1007/s10439-014-1207-1.
D.L. Elbert, Liquid-liquid two phase systems for the production of porous
hydrogels and hydrogel microspheres for biomedical applications: a tutorial
review, Acta Biomater. 7 (2012) 31e56, http://dx.doi.org/10.1016/
j.actbio.2010.07.028.
R. Mooney, S. Haeger, R. Lawal, M. Mason, N. Shrestha, A. Laperle, et al.,
Control of neural cell composition in poly(ethylene glycol) hydrogel culture
with soluble factors, Tissue Eng. Part A 17 (2011) 2805e2815, http://
dx.doi.org/10.1089/ten.tea.2010.0654.
S. Giovagnoli, T. Tsai, P.P. DeLuca, Formulation and release behavior of
doxycycline-alginate hydrogel microparticles embedded into pluronic F127
thermogels as a potential new vehicle for doxycycline intradermal sustained
delivery, AAPS PharmSciTech 11 (2010) 212e220, http://dx.doi.org/10.1208/
s12249-009-9361-8.
S.N.S. Alconcel, A.S. Baas, H.D. Maynard, FDA-approved poly(ethylene glycol)eprotein conjugate drugs, Polym. Chem. 2 (2011) 1442, http://
dx.doi.org/10.1039/c1py00034a.
F.M. Veronese, G. Pasut, PEGylation, successful approach to drug delivery,
Drug Discov. Today 10 (2005) 1451e1458, http://dx.doi.org/10.1016/S13596446(05)03575-0.
L. Hockaday, K.H. Kang, N.W. Colangelo, P.Y.C. Cheung, B. Duan, E. Malone, et
al., Rapid 3D printing of anatomically accurate and mechanically heterogeneous aortic valve hydrogel scaffolds, Biofabrication 4 (2012) 035005, http://
dx.doi.org/10.1088/1758-5082/4/3/035005.
M. Zhang, T. Desai, M. Ferrari, Proteins and cells on PEG immobilized silicon
surfaces, Biomaterials 19 (1998) 953e960, http://dx.doi.org/10.1016/S01429612(98)00026-X.
N.E. Fedorovich, J. Alblas, J.R. de Wijn, W.E. Hennink, A.J. Verbout, W.J. Dhert,
Hydrogels as extracellular matrices for skeletal tissue engineering: state-ofthe-art and novel application in organ printing, Tissue Eng. 13 (2007)
1905e1925, http://dx.doi.org/10.1089/ten.2006.0175.
P. Serwer, J.L. Allen, S.J. Hayes, Agarose gel electrophoresis of bacteriophages
and related particles III. Dependence of gel sieving on the agarose preparation, Electrophoresis 4 (1983) 232e236, http://dx.doi.org/10.1002/
elps.1150040309.
R. Landers, U. Hübner, R. Schmelzeisen, R. Mülhaupt, Rapid prototyping of
scaffolds derived from thermoreversible hydrogels and tailored for applications in tissue engineering, Biomaterials 23 (2002) 4437e4447, http://
dx.doi.org/10.1016/S0142-9612(02)00139-4.
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
[121] H.A. Awad, M.Q. Wickham, H. Leddy, J.M. Gimble, F. Guilak, Chondrogenic
differentiation of adipose-derived adult stem cells in agarose, alginate, and
gelatin scaffolds, Biomaterials 25 (2004) 3211e3222, http://dx.doi.org/
10.1016/j.biomaterials.2003.10.045.
€kel, S. Neuss, W. Jahnen[122] D.F. Duarte Campos, A. Blaeser, M. Weber, J. Ja
Dechent, et al., Three-dimensional printing of stem cell-laden hydrogels
submerged in a hydrophobic high-density fluid, Biofabrication 5 (2013)
015003, http://dx.doi.org/10.1088/1758-5082/5/1/015003.
[123] D.M. Dean, A.P. Napolitano, J. Youssef, J.R. Morgan, Rods, tori, and honeycombs: the directed self-assembly of microtissues with prescribed microscale geometries, FASEB J. 21 (2007) 4005e4012, http://dx.doi.org/10.1096/
fj.07-8710com.
[124] V. Mironov, V. Kasyanov, R.R. Markwald, Organ printing: from bioprinter to
organ biofabrication line, Curr. Opin. Biotechnol. 22 (2011) 667e673, http://
dx.doi.org/10.1016/j.copbio.2011.02.006.
[125] M. Achilli, D. Mantovani, Tailoring mechanical properties of collagen-based
Scaffolds for vascular tissue engineering: the effects of pH, temperature
and ionic strength on gelation, Polymers (Basel) 2 (2010) 664e680, http://
dx.doi.org/10.3390/polym2040664.
[126] P.G. Robey, Wojciech J. Grzesik, Bone matrix RGD glycoproteins: immunolocalization bone cells in vitro, J. Bone Min. Res. 9 (1994) 487e496, http://
dx.doi.org/10.1002/jbmr.5650090408.
[127] M. Rücker, M.W. Laschke, D. Junker, C. Carvalho, A. Schramm, R. Mülhaupt, et
al., Angiogenic and inflammatory response to biodegradable scaffolds in
dorsal skinfold chambers of mice, Biomaterials 27 (2006) 5027e5038, http://
dx.doi.org/10.1016/j.biomaterials.2006.05.033.
[128] C. Helary, I. Bataille, A. Abed, C. Illoul, A. Anglo, L. Louedec, et al., Concentrated collagen hydrogels as dermal substitutes, Biomaterials 31 (2010)
481e490, http://dx.doi.org/10.1016/j.biomaterials.2009.09.073.
[129] A. Skardal, D. Mack, E. Kapetanovic, A. Atala, J. Jackson, J. Yoo, et al., Bioprinted amniotic fluid-derived stem cells accelerate healing of large skin
wounds, Stem Cells Transl. Med. (2012) 792e802, http://dx.doi.org/10.5966/
sctm.2012-0088.
[130] C.C. Chang, E.D. Boland, S.K. Williams, J.B. Hoying, Direct-write bioprinting
three-dimensional biohybrid systems for future regenerative therapies,
J. Biomed. Mater. Res. B Appl. Biomater. 98 (2011) 160e170, http://
dx.doi.org/10.1002/jbm.b.31831.
[131] L. Xi, T. Wang, F. Zhao, Q. Zheng, X. Li, J. Luo, et al., Evaluation of an injectable
thermosensitive hydrogel as drug delivery implant for ocular glaucoma
surgery, PLoS One 9 (2014) 571e582, http://dx.doi.org/10.1371/
journal.pone.0100632.
[132] W. Wu, A. DeConinck, J. Lewis, Omnidirectional printing of 3D microvascular
networks, Adv. Mater. 23 (2011) H178eH183, http://dx.doi.org/10.1002/
adma.201004625.
[133] C.M. Homenick, G. de Silveira, H. Sheardown, A. Adronov, Pluronics as
crosslinking agents for collagen: novel amphiphilic hydrogels, Polym. Int. 60
(2011) 458e465, http://dx.doi.org/10.1002/pi.2969.
[134] H.K. Kleinman, G.R. Martin, Matrigel: basement membrane matrix with
biological activity, Semin. Cancer Biol. 15 (2005) 378e386, http://dx.doi.org/
10.1016/j.semcancer.2005.05.004.
[135] Z. Li, J. Guan, Hydrogels for cardiac tissue engineering, Polymers 3 (2011)
740e761, http://dx.doi.org/10.3390/polym3020740.
[136] N.E. Fedorovich, J.R. De Wijn, A.J. Verbout, J. Alblas, W.J. Dhert, Threedimensional fiber deposition of cell-laden, viable, patterned constructs for
bone tissue printing, Tissue Eng. Part A 14 (2008) 127e133, http://
dx.doi.org/10.1089/ten.a.2007.0158.
[137] N.E. Fedorovich, H.M. Wijnberg, W.J. Dhert, J. Alblas, Distinct tissue formation by heterogeneous printing of osteo- and endothelial progenitor cells,
Tissue Eng. Part A 17 (2011) 2113e2121, http://dx.doi.org/10.1089/
ten.tea.2011.0019.
[138] J.R. Lott, J.W. McAllister, S. Arvidson, F.S. Bates, T.P. Lodge, Fibrillar structure
of methylcellulose hydrogels, Biomacromolecules 14 (2013) 2484e2488,
http://dx.doi.org/10.1021/bm400694r.
[139] K. Kobayashi, C. Huang, T.P. Lodge, Thermoreversible gelation of aqueous
methylcellulose solutions, Macromolecules 32 (1999) 7070e7077, http://
dx.doi.org/10.1021/ma990242n.
[140] S. Thirumala, J. Gimble, R. Devireddy, Methylcellulose based thermally
reversible hydrogel system for tissue engineering applications, Cells 2 (2013)
460e475, http://dx.doi.org/10.3390/cells2030460.
[141] C. Trojani, P. Weiss, J.F. Michiels, C. Vinatier, J. Guicheux, G. Daculsi, et al.,
Three-dimensional culture and differentiation of human osteogenic cells in
an injectable hydroxypropylmethylcellulose hydrogel, Biomaterials 26
(2005) 5509e5517, http://dx.doi.org/10.1016/j.biomaterials.2005.02.001.
[142] C. Vinatier, D. Magne, P. Weiss, C. Trojani, N. Rochet, G.F. Carle, et al.,
A silanized hydroxypropyl methylcellulose hydrogel for the threedimensional culture of chondrocytes, Biomaterials 26 (2005) 6643e6651,
http://dx.doi.org/10.1016/j.biomaterials.2005.04.057.
[143] C. Wu, Y. Luo, G. Cuniberti, Y. Xiao, M. Gelinsky, Three-dimensional printing
of hierarchical and tough mesoporous bioactive glass scaffolds with a
controllable pore architecture, excellent mechanical strength and mineralization ability, Acta Biomater. 7 (2011) 2644e2650, http://dx.doi.org/
10.1016/j.actbio.2011.03.009.
€gg,
[144] K. Markstedt, A. Mantas, I. Tournier, H. Martínez Avila,
D. Ha
P. Gatenholm, 3D bioprinting human chondrocytes with nanocellulosealginate
bioink
for
cartilage
tissue
engineering
applications,
[145]
[146]
[147]
[148]
[149]
[150]
[151]
[152]
[153]
[154]
[155]
[156]
[157]
[158]
[159]
[160]
[161]
[162]
[163]
[164]
[165]
[166]
[167]
341
Biomacromolecules (2015), http://dx.doi.org/10.1021/acs.biomac.5b00188,
150325142328001.
H. Li, Y. Dai, J. Shu, R. Yu, Y. Guo, J. Chen, Spheroid cultures promote the
stemness of corneal stromal cells, Tissue Cell 47 (2015) 39e48, http://
dx.doi.org/10.1016/j.tice.2014.10.008.
Y. Yu, M.J. Brouillette, D. Seol, H. Zheng, J.A. Buckwalter, J.A. Martin, Functional full-thickness articular cartilage repair by rhSDF-1a loaded fibrin/HA
hydrogel network via chondrogenic progenitor cells homing, Arthritis
Rheum. (2012) 1e30, http://dx.doi.org/10.1002/art.
Y.-B. Lee, S. Polio, W. Lee, G. Dai, L. Menon, R.S. Carroll, et al., Bio-printing of
collagen and VEGF-releasing fibrin gel scaffolds for neural stem cell culture,
http://dx.doi.org/10.1016/
Exp.
Neurol.
223
(2010)
645e652,
j.expneurol.2010.02.014.
T. Xu, C. Gregory, P. Molnar, X. Cui, S. Jalota, S.B. Bhaduri, et al., Viability and
electrophysiology of neural cell structures generated by the inkjet printing
method, Biomaterials 27 (2006) 3580e3588, http://dx.doi.org/10.1016/
j.biomaterials.2006.01.048.
X. Cui, T. Boland, Human microvasculature fabrication using thermal inkjet
printing technology, Biomaterials 30 (2009) 6221e6227, http://dx.doi.org/
10.1016/j.biomaterials.2009.07.056.
Wei Xu, Xiaohong Wang, Yongnian Yan, Wei Zheng, Zhuo Xiong, Feng Lin, et
al., Rapid prototyping three-dimensional cell/gelatin/fibrinogen constructs
for medical regeneration, J. Bioact. Compat. Polym. 22 (2007) 363e377,
http://dx.doi.org/10.1177/0883911507079451.
C. Li, A. Faulkner-Jones, A.R. Dun, J. Jin, P. Chen, Y. Xing, et al., Rapid formation of a supramolecular polypeptide-DNA hydrogel for in situ threedimensional multilayer bioprinting, Angew. Chem. Int. Ed. Engl. (2015)
1e6, http://dx.doi.org/10.1002/anie.201411383.
I.T. Ozbolat, B. Koc, Modeling of spatially controlled biomolecules in threedimensional porous alginate structures, J. Med. Device 4 (2010) 041003,
http://dx.doi.org/10.1115/1.4002612.
I.T. Ozbolat, B. Koc, Multi-function based modeling of 3D heterogeneous
wound scaffolds for improved wound healing, Comput. Aided Des. Appl. 8
(2011) 43e57, http://dx.doi.org/10.3722/cadaps.2011.43-57.
L. Mogas-Soldevila, J. Duro-Royo, N. Oxman, Water-based Robotic fabrication: large-scale additive manufacturing of functionally graded hydrogel
composites via multichamber extrusion, 3D Print. Addit. Manuf. 1 (2014)
141e151, http://dx.doi.org/10.1089/3dp.2014.0014.
I. Ozbolat, Scaffold-based or Scaffold-free bioprinting: competing or complementing approaches? J. Nanotechnol. Eng. Med. 6 (2015) 024701, http://
dx.doi.org/10.1115/1.4030414.
J. Yu, K.L. Christman, E. Chin, R.E. Sievers, M. Saeed, R.J. Lee, Restoration of left
ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathy, J. Thorac. Cardiovasc. Surg.
137 (2009) 180e187, http://dx.doi.org/10.1016/j.jtcvs.2008.08.036.
M. Gruene, M. Pflaum, C. Hess, S. Diamantouros, S. Schlie, A. Deiwick, et al.,
Laser printing of three-dimensional multicellular arrays for studies of
cellecell and celleenvironment interactions, Tissue Eng. Part C Methods 17
(2011) 973e982, http://dx.doi.org/10.1089/ten.tec.2011.0185.
J. Malda, C. van Blitterswijk, M. Grojec, D.E. Martens, J. Tramper, J. Riesle,
Expansion of bovine chondrocytes on microcarriers enhances redifferentiation, Tissue Eng. 9 (2003) 939e948, http://dx.doi.org/10.1089/
107632703322495583.
, C. Nickerson, G.D. Prestwich, The generation
A. Skardal, S.F. Sarker, A. Crabbe
of 3-D tissue models based on hyaluronan hydrogel-coated microcarriers
within a rotating wall vessel bioreactor, Biomaterials 31 (2010) 8426e8435,
http://dx.doi.org/10.1016/j.biomaterials.2010.07.047.
S.J. Curran, R. Chen, J.M. Curran, J. Hunt, Expansion of human chondrocytes in
an intermittent stirred flow bioreactor, using modified biodegradable microspheres, Tissue Eng. 11 (2005) 1312e1322, http://dx.doi.org/10.1089/
ten.2005.11.1312.
Y. Bayram, M. Deveci, N. Imirzalioglu, Y. Soysal, M. Sengezer, The cell based
dressing with living allogenic keratinocytes in the treatment of foot ulcers: a
case study, Br. J. Plast. Surg. 58 (2005) 988e996, http://dx.doi.org/10.1016/
j.bjps.2005.04.031.
J.Y. Liu, J. Hafner, G. Dragieva, B. Seifert, G. Burg, Autologous cultured keratinocytes on porcine gelatin microbeads effectively heal chronic venous leg
ulcers, Wound Repair Regen. 12 (2004) 148e156, http://dx.doi.org/10.1111/
j.1067-1927.2004.012205.x.
A.H. Shikani, D.J. Fink, A. Sohrabi, P. Phan, A. Polotsky, D.S. Hungerford, et al.,
Propagation of human nasal chondrocytes in microcarrier spinner culture,
Am. J. Rhinol. 18 (2004) 105e112.
M. Overstreet, A. Sohrabi, A. Polotsky, D.S. Hungerford, C.G. Frondoza,
Collagen microcarrier spinner culture promotes osteoblast proliferation and
synthesis of matrix proteins, In Vitro Cell. Dev. Biol. Anim. 39 (2003)
228e234, http://dx.doi.org/10.1290/1543-706X(2003)039.
M. Yamamoto, D. James, H. Li, J. Butler, S. Rafii, S. Rabbany, Generation of
stable co-cultures of vascular cells in a honeycomb alginate scaffold, Tissue
Eng. Part A 16 (2010) 299e308, http://dx.doi.org/10.1089/ten.tea.2009.0010.
B. Liau, N. Christoforou, K.W. Leong, N. Bursac, Pluripotent stem cell-derived
cardiac tissue patch with advanced structure and function, Biomaterials 32
(2011) 9180e9187, http://dx.doi.org/10.1016/j.biomaterials.2011.08.050.
D. Zhang, I.Y. Shadrin, J. Lam, H.Q. Xian, H.R. Snodgrass, N. Bursac, Tissueengineered cardiac patch for advanced functional maturation of human ESCderived cardiomyocytes, Biomaterials 34 (2013) 5813e5820, http://
342
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
dx.doi.org/10.1016/j.biomaterials.2013.04.026.
[168] S. Breslin, L. O'Driscoll, Three-dimensional cell culture: the missing link in
drug discovery, Drug Discov. Today 18 (2013) 240e249 doi: http://dx.doi.
org/10.1016/j.drudis.2012.10.003.
[169] Y. Torisawa, B. Mosadegh, G.D. Luker, M. Morell, K.S. O'Shea, S. Takayama,
Microfluidic hydrodynamic cellular patterning for systematic formation of
co-culture spheroids, Integr. Biol. (Camb.) 1 (2009) 649e654, http://
dx.doi.org/10.1039/b915965g.
[170] A.Y. Hsiao, Y.S. Torisawa, Y.C. Tung, S. Sud, R.S. Taichman, K.J. Pienta, et al.,
Microfluidic system for formation of PC-3 prostate cancer co-culture
spheroids, Biomaterials 30 (2009) 3020e3027, http://dx.doi.org/10.1016/
j.biomaterials.2009.02.047.
[171] A. Khademhosseini, L. Ferreira, J. Blumling, J. Yeh, J.M. Karp, J. Fukuda, et al.,
Co-culture of human embryonic stem cells with murine embryonic fibroblasts on microwell-patterned substrates, Biomaterials 27 (2006)
5968e5977, http://dx.doi.org/10.1016/j.biomaterials.2006.06.035.
[172] Y. Tan, D.J. Richards, T.C. Trusk, R.P. Visconti, M.J. Yost, M.S. Kindy, et al., 3D
printing facilitated scaffold-free tissue unit fabrication, Biofabrication 6
(2014) 024111, http://dx.doi.org/10.1088/1758-5082/6/2/024111.
[173] A. Akkouch, Y. Yu, I.T. Ozbolat, Microfabrication of scaffold-free tissue
strands for three-dimensional tissue engineering, Biofabrication 7 (2015)
31002, http://dx.doi.org/10.1088/1758-5090/7/3/031002.
[174] I.T. Ozbolat, Y. Yu, Bioprinting toward organ fabrication: challenges and
http://dx.doi.org/10.1109/
future
trends
60
(2013)
691e699,
TBME.2013.2243912.
[175] T. Achilli, J. Meyer, J.R. Morgan, Advances in the formation, use and understanding of multi- cellular spheroids, Expert Opin. Biol. Ther. 12 (2012)
1347e1360, http://dx.doi.org/10.1517/14712598.2012.707181.Advances.
[176] T. Katakai, T. Hara, J.H. Lee, H. Gonda, M. Sugai, A. Shimizu, A novel reticular
stromal structure in lymph node cortex: an immuno-platform for interactions among dendritic cells, T cells and B cells, Int. Immunol. 16 (2004)
1133e1142, http://dx.doi.org/10.1093/intimm/dxh113.
[177] C. Kucukgul, S.B. Ozler, I. Inci, E. Karakas, S. Irmak, D. Gozuacik, et al., 3D
bioprinting of biomimetic aortic vascular constructs with self-supporting
cells, Biotechnol. Bioeng. 112 (2014), http://dx.doi.org/10.1002/bit.25493.
[178] H. Ott, T. Matthiesen, S.-K. Goh, L. Black, S. Kren, T. Netoff, et al., Perfusiondecellularized matrix: using nature's platform to engineer a bioartificial
heart, Nat. Med. 14 (2008) 213e221, http://dx.doi.org/10.1038/nm1684.
[179] T.-Y. Lu, B. Lin, J. Kim, M. Sullivan, K. Tobita, G. Salama, et al., Repopulation of
decellularized mouse heart with human induced pluripotent stem cellderived cardiovascular progenitor cells, Nat. Commun. 4 (2013), http://
dx.doi.org/10.1038/ncomms3307.
[180] J.J. Song, J.P. Guyette, S.E. Gilpin, G. Gonzalez, J.P. Vacanti, H.C. Ott, Regeneration and experimental orthotopic transplantation of a bioengineered
kidney, Nat. Med. 19 (2013) 646e651, http://dx.doi.org/10.1038/nm.3154.
[181] B.E. Uygun, A. Soto-Gutierrez, H. Yagi, M.-L. Izamis, M. Guzzardi, C. Shulman,
et al., Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix, Nat. Med. 16 (2010)
814e820, http://dx.doi.org/10.1038/nm.2170.
[182] K.E.M. Benders, P.R. Van Weeren, S.F. Badylak, D.B.F. Saris, W.J. Dhert,
J. Malda, Extracellular matrix scaffolds for cartilage and bone regeneration,
Trends Biotechnol. 31 (2013) 169e176, http://dx.doi.org/10.1016/
j.tibtech.2012.12.004.
[183] C. Conrad, C. Schuetz, B. Clippinger, J.P. Vacanti, J.F. Markmann, H.C. Ott, Bioengineered endocrine pancreas based on decellularized pancreatic matrix
and mesenchymal stem cell/islet cell coculture, J. Am. Coll. Surg. 211 (2010)
S62, http://dx.doi.org/10.1016/j.jamcollsurg.2010.06.161.
[184] J.J. Song, H.C. Ott, Organ engineering based on decellularized matrix scaffolds, Trends Mol. Med. 17 (2011) 424e432 doi: http://dx.doi.org/10.1016/j.
molmed.2011.03.005.
[185] S. Coatnye, B. Gandhi, B. Park, D. Dzilno, E. Tapia, G. Kamarthy, et al., 3D Bioprinting, Tech. Rep. No. 2013.04.17, 2013.
[186] J.-H. Shim, J.-S. Lee, J.Y. Kim, D.-W. Cho, Bioprinting of a mechanically
enhanced three-dimensional dual cell-laden construct for osteochondral
tissue engineering using a multi-head tissue/organ building system,
J. Micromechanics Microeng. 22 (2012) 085014, http://dx.doi.org/10.1088/
0960-1317/22/8/085014.
[187] E. Malone, H. Lipson, Fab@Home: the personal desktop fabricator kit, Rapid
http://dx.doi.org/10.1108/
Prototyp.
J.
13
(2007)
245e255,
13552540710776197.
[188] Root Analysis Business Research & Consulting, 3D Bioprinting Market,
2014e2030, 2014.
[189] V.K. Lee, D.Y. Kim, H. Ngo, Y. Lee, L. Seo, S.-S. Yoo, et al., Creating perfused
functional vascular channels using 3D bio-printing technology, Biomaterials
35 (2014) 8092e8102 doi: http://dx.doi.org/10.1016/j.biomaterials.2014.05.
083.
[190] Q. Gao, Y. He, J. Fu, A. Liu, L. Ma, Coaxial nozzle-assisted 3D bioprinting with
built-in microchannels for nutrients delivery, Biomaterials 61 (2015)
203e215, http://dx.doi.org/10.1016/j.biomaterials.2015.05.031.
[191] Y. Zhang, Y. Yu, H. Chen, I.T. Ozbolat, Characterization of printable cellular
micro-fluidic channels for tissue engineering, Biofabrication. 5 (2013) 24004.
http://dx.doi.org/10.1088/1758-5082/5/2/025004.
[192] F. Dolati, Y. Yu, Y. Zhang, A. Jesus, E.A. Sander, I.T. Ozbolat, In vitro evaluation
of carbon-nanotube-reinforced bioprintable vascular conduits, Nanotechnology 25 (2014) 145101. http://stacks.iop.org/0957-4484/25/i¼14/
a¼145101.
[193] L.E. Bertassoni, M. Cecconi, V. Manoharan, M. Nikkhah, J. Hjortnaes,
A.L. Cristino, et al., Hydrogel bioprinted microchannel networks for vascularization of tissue engineering constructs, Lab Chip 14 (2014) 2202e2211,
http://dx.doi.org/10.1039/c4lc00030g.
[194] L. Zhao, V.K. Lee, S.-S. Yoo, G. Dai, X. Intes, The integration of 3-D cell printing
and mesoscopic fluorescence molecular tomography of vascular constructs
within thick hydrogel scaffolds, Biomaterials 33 (2012) 5325e5332, http://
dx.doi.org/10.1016/j.biomaterials.2012.04.004.
[195] M.S. Ozturk, V.K. Lee, L. Zhao, G. Dai, X. Intes, Mesoscopic fluorescence
molecular tomography of reporter genes in bioprinted thick tissue,
J.
Biomed.
Opt.
18
(2013)
100501,
http://dx.doi.org/10.1117/
1.JBO.18.10.100501.
[196] J.S. Miller, K.R. Stevens, M.T. Yang, B.M. Baker, D.-H.T. Nguyen, D.M. Cohen, et
al., Rapid casting of patterned vascular networks for perfusable engineered
three-dimensional tissues, Nat. Mater. 11 (2012) 768e774. http://dx.doi.org/
10.1038/nmat3357.
[197] V. Lee, A. Lanzi, H. Ngo, S.-S. Yoo, P. Vincent, G. Dai, Generation of multi-scale
vascular network system within 3D hydrogel using 3D bio-printing technology, Cell. Mol. Bioeng. (2014) 1e13, http://dx.doi.org/10.1007/s12195014-0340-0.
[198] S. Chung, R. Sudo, P.J. Mack, C.-R. Wan, V. Vickerman, R.D. Kamm, Cell
migration into scaffolds under co-culture conditions in a microfluidic platform, Lab Chip 9 (2009) 269e275, http://dx.doi.org/10.1039/b807585a.
[199] W. Sheng, O.O. Ogunwobi, T. Chen, J. Zhang, T.J. George, C. Liu, et al., Capture,
release and culture of circulating tumor cells from pancreatic cancer patients
using an enhanced mixing chip, Lab Chip 14 (2014) 89e98, http://dx.doi.org/
10.1039/c3lc51017d.
[200] W.-Y. Yeong, C.-K. Chua, K.-F. Leong, M. Chandrasekaran, Rapid prototyping
in tissue engineering: challenges and potential, Trends Biotechnol. 22 (2004)
643e652, http://dx.doi.org/10.1016/j.tibtech.2004.10.004.
[201] Y. Yu, Y. Zhang, J. Martin, I.T. Ozbolat, Evaluation of cell viability and functionality in vessel-like bioprintable cell-laden tubular channels, J. Biomech.
Eng. 135 (2013) 91011, http://dx.doi.org/10.1115/1.4024575.
[202] Nordson EFD, http://www.nordson.com (2015).
[203] D.A. Bruzewicz, M. Reches, G.M. Whitesides, Low-cost printing of poly(dimethylsiloxane) barriers to define microchannels in paper, Anal. Chem. 80
(2008) 3387e3392, http://dx.doi.org/10.1021/ac702605a.
[204] S.B. Bammesberger, S. Kartmann, L. Tanguy, D. Liang, K. Mutschler, A. Ernst,
et al., A low-cost, normally closed, solenoid valve for non-contact dispensing
in the sub-ml range, Micromachines 4 (2013) 9e21, http://dx.doi.org/
10.3390/mi4010009.
[205] I.T. Ozbolat, Bioprinting scale-up tissue and organ constructs for transplantation, Trends Biotechnol. (2015) 1e6, http://dx.doi.org/10.1016/
j.tibtech.2015.04.005.
[206] L. Koch, S. Kuhn, H. Sorg, M. Gruene, S. Schlie, R. Gaebel, et al., Laser printing
of skin cells and human stem cells, Tissue Eng. Part C. Methods 16 (2010)
847e854, http://dx.doi.org/10.1089/ten.tec.2009.0397.
[207] Z. Wang, W. Wu, Q. Yang, Y. Li, C.H. Noh, In-situ fabrication of flexible
vertically integrated electronic circuits by inkjet printing, J. Alloys Compd.
486 (2009) 706e710, http://dx.doi.org/10.1016/j.jallcom.2009.07.044.
[208] I. Hussain, S.Z. Hussain, Habib-ur-Rehman, A. Ihsan, A. Rehman, Z.M. Khalid,
et al., In situ growth of gold nanoparticles on latent fingerprints-from
forensic applications to inkjet printed nanoparticle patterns, Nanoscale 2
(2010) 2575e2578, http://dx.doi.org/10.1039/c0nr00593b.
[209] A.J. Lopes, I.H. Lee, E. Macdonald, R. Quintana, R. Wicker, Laser curing of
silver-based conductive inks for in situ 3D structural electronics fabrication
in stereolithography, J. Mater. Process. Technol. 214 (2014) 1935e1945,
http://dx.doi.org/10.1016/j.jmatprotec.2014.04.009.
[210] T. Xu, K.W. Binder, M.Z. Albanna, D. Dice, W. Zhao, J.J. Yoo, et al., Hybrid
printing of mechanically and biologically improved constructs for cartilage
tissue engineering applications, Biofabrication 5 (2013) 015001, http://
dx.doi.org/10.1088/1758-5082/5/1/015001.
[211] E.D.F. Ker, B. Chu, J. Phillippi, B. Gharaibeh, J. Huard, L.E. Weiss, et al., Engineering spatial control of multiple differentiation fates within a stem cell
population, Biomaterials 32 (2011) 3413e3422, http://dx.doi.org/10.1016/
j.biomaterials.2011.01.036.
[212] J.K. Carrow, A.K. Gaharwar, Bioinspired Polymeric Nanocomposites for
Regenerative Medicine, Macromol. Chem. Phys. (2014), http://dx.doi.org/
10.1002/macp.201400427 n/aen/a.
[213] M.A. Kay, State-of-the-art gene-based therapies: the road ahead, Nat. Rev.
Genet. 12 (2011) 316e328. http://dx.doi.org/10.1038/nrg2971.
[214] C.H. Evans, S.C. Ghivizzani, P.D. Robbins, Progress and prospects: genetic
treatments for disorders of bones and joints, Gene Ther. 16 (2009) 944e952.
http://dx.doi.org/10.1038/gt.2009.73.
[215] S. Elangovan, S.R. D'Mello, L. Hong, R.D. Ross, C. Allamargot, D.V. Dawson, et
al., The enhancement of bone regeneration by gene activated matrix
encoding for platelet derived growth factor, Biomaterials 35 (2014) 737e747
doi: http://dx.doi.org/10.1016/j.biomaterials.2013.10.021.
[216] T. Aper, O.E. Teebken, G. Steinhoff, A. Haverich, Use of a fibrin preparation in
the engineering of a vascular graft model, Eur. J. Vasc. Endovasc. Surg. 28
(2004) 296e302, http://dx.doi.org/10.1016/j.ejvs.2004.05.016.
[217] J.W. Nichol, S.T. Koshy, H. Bae, C.M. Hwang, S. Yamanlar, A. Khademhosseini,
Cell-laden microengineered gelatin methacrylate hydrogels, Biomaterials 31
(2010) 5536e5544, http://dx.doi.org/10.1016/j.biomaterials.2010.03.064.
I.T. Ozbolat, M. Hospodiuk / Biomaterials 76 (2016) 321e343
[218] M.S. Mannoor, Z. Jiang, T. James, Y.L. Kong, K.A. Malatesta, W.O. Soboyejo,
N. Verma, D.H. Gracias, M.C. McAlpine, 3D printed bionic ears, Nano Lett. 13
(2013) 2634e2639. http://pubs.acs.org/doi/abs/10.1021/nl4007744.
[219] J.R. Gallant, L.L. Traeger, J.D. Volkening, H. Moffett, et al., Genomic basis for
the convergent evolution of electric organs, Science 344 (2014) 1522e1525,
http://dx.doi.org/10.1126/science.1254432.
[220] B. Fritzsch, Electric organs: history and potential, Science 345 (2014)
631e632, http://dx.doi.org/10.1126/science.345.6197.631-b.
[221] K.B. Hellman, Tissue engineering: translating science to product, in: Topics in
Tissue Eng, 2008, pp. 1e28.
[222] N.E. Fedorovich, W. Schuurman, H.M. Wijnberg, H.-J. Prins, P.R. van Weeren,
J. Malda, et al., Biofabrication of osteochondral tissue equivalents by printing
topologically defined, cell-laden hydrogel scaffolds, Tissue Eng. Part C
Methods 18 (2012) 33e44, http://dx.doi.org/10.1089/ten.TEC.2011.0060.
[223] J.-S. Lee, J.M. Hong, J.W. Jung, J.-H. Shim, J.-H. Oh, D.-W. Cho, 3D printing of
composite tissue with complex shape applied to ear regeneration, Biofabrication 6 (2014) 024103, http://dx.doi.org/10.1088/1758-5082/6/2/024103.
[224] V. Lee, G. Singh, J.P. Trasatti, C. Bjornsson, X. Xu, T.N. Tran, et al., Design and
fabrication of human skin by three-dimensional bioprinting, Tissue Eng. Part
C
Methods
20
(2014)
473e484,
http://dx.doi.org/10.1089/
ten.TEC.2013.0335.
[225] W. Lee, J. Pinckney, V. Lee, J.-H. Lee, K. Fischer, S. Polio, et al., Threedimensional bioprinting of rat embryonic neural cells, Neuroreport 20
(2009) 798e803, http://dx.doi.org/10.1097/WNR.0b013e32832b8be4.
[226] A. Tocchio, M. Tamplenizza, F. Martello, I. Gerges, E. Rossi, S. Argentiere, et
al., Versatile fabrication of vascularizable scaffolds for large tissue engineering in bioreactor, Biomaterials 45 (2015) 124e131, http://dx.doi.org/
10.1016/j.biomaterials.2014.12.031.
[227] S.F. Khattak, S.R. Bhatia, S.C. Roberts, Pluronic F127 as a cell encapsulation
material: utilization of membrane-stabilizing agents, Tissue Eng. 11 (2005)
974e983, http://dx.doi.org/10.1089/ten.2005.11.974.
[228] A. Skardal, J. Zhang, L. McCoard, S. Oottamasathien, G.D. Prestwich,
Dynamically crosslinked gold nanoparticle e hyaluronan hydrogels, Adv.
Mater. 22 (2010) 4736e4740, http://dx.doi.org/10.1002/adma.201001436.
[229] F. Pati, J.H. Shim, J.S. Lee, D.W. Cho, 3D printing of cell-laden constructs for
heterogeneous tissue regeneration, Manuf. Lett. 1 (2013) 49e53, http://
dx.doi.org/10.1016/j.mfglet.2013.09.004.
[230] S.J. Song, J. Choi, Y.D. Park, J.J. Lee, S.Y. Hong, K. Sun, A three-dimensional
bioprinting system for use with a hydrogel-based biomaterial and printing
parameter characterization, Artif. Organs 34 (2010) 1044e1048, http://
dx.doi.org/10.1111/j.1525-1594.2010.01143.x.
[231] S.J. Song, J. Choi, Y.D. Park, S. Hong, J.J. Lee, C.B. Ahn, et al., Sodium alginate
[232]
[233]
[234]
[235]
[236]
[237]
[238]
[239]
[240]
[241]
[242]
343
hydrogel-based bioprinting using a novel multinozzle bioprinting system,
Artif. Organs 35 (2011) 1132e1136, http://dx.doi.org/10.1111/j.15251594.2011.01377.x.
S. Hong, S.J. Song, J.Y. Lee, H. Jang, J. Choi, K. Sun, et al., Cellular behavior in
micropatterned hydrogels by bioprinting system depended on the cell types
and cellular interaction, J. Biosci. Bioeng. 116 (2013) 224e230, http://
dx.doi.org/10.1016/j.jbiosc.2013.02.011.
G.Y. Huang, L.H. Zhou, Q.C. Zhang, Y.M. Chen, W. Sun, F. Xu, et al., Microfluidic hydrogels for tissue engineering, Biofabrication 3 (2011) 012001,
http://dx.doi.org/10.1088/1758-5082/3/1/012001.
H. Kang, I. Ko, C. Kim, S. Lee, A. Atala, J. Yoo, Biofabrication of innervated
muscle tissue for accelerated restoration of muscle function, Soc. Biomaterials 29 (2013) 27157.
G. Edwin, B. Emilie, H. Edward, S. Koen, P. Sharon, H. Deborah, et al., Threedimensional (3D) bone tissues derived from stem cells as a novel model for
mineralization, in: Stem Cell Meeting on the Mesa, La Jolla, CA, 2014.
J.B. Robbins, C.M.O. Neill, V. Gorgen, S.C. Presnell, B.R. Shepherd, N. Ridge, et
al., Bioprinted three-dimensional (3D) human liver constructs provide a
model for interrogating liver biology, Mol. Biol. Cell (2013) 963. New
Orleans, LA.
J.B. Robbins, G. Vivian, M. Peter, B. Shephard, S. Presnell, A Novel in Vitro 3D
Bioprinted Liver Tissue System for Drug Development, The American Society
of Experimental Biology, Boston, MA, 2013.
S.M. King, V. Gorgen, S.C. Presnell, D.G. Nguyen, B.R. Shepherd, N. Ridge, et
al., Development of 3D Bioprinted Human Breast Cancer for in Vitro
Screening of Therapeutics Targeted Against Cancer Progression, American
Soceity of Biology, New Orleans, LA, 2013.
K.B. Chien, E. Makridakis, R.N. Shah, Three dimensional printing of soy
protein Scaffolds for tissue regeneration, Tissue Eng. Part C Methods 19
(2012), http://dx.doi.org/10.1089/ten.TEC.2012.0383, 121026142624002.
N.T. Ersumo, K.L. Spiller, A.B. Selection, Effects of hydrogel properties and
extrusion parameters on 3D bioprinting, in: Biomedical Engineering Conference, 2015, pp. 25e26, http://dx.doi.org/10.1109/NEBEC.2015.7117090.
M.S. Mannoor, Z. Jiang, T. James, Y.L. Kong, K.A. Malatesta, W.O. Soboyejo, et
al., 3D printed bionic ears, Nano Lett. 13 (2013) 2634e2639, http://
dx.doi.org/10.1021/nl4007744.
H. Seyednejad, D. Gawlitta, W.J.A. Dhert, C.F. Van Nostrum, T. Vermonden,
W.E. Hennink, Preparation and characterization of a three-dimensional
printed scaffold based on a functionalized polyester for bone tissue engineering applications, Acta Biomater. 7 (2011) 1999e2006, http://dx.doi.org/
10.1016/j.actbio.2011.01.018.